Stock Sectors

Biotechnology

Stock Charts – Click sector to view stock chart

AMARIN CORPORATION PLC - AMERICAN DEPOSITARY SHARES EACH REPRESENTING ONE ORDINARY SHARE (AMRN)

Amarin Corporation plc, a neuroscience pharmaceutical company, engages in the development and commercialization of novel drugs for the treatment of neurological disorders affecting the central nervous system. The company's principal compound, Miraxion, is in phase III development for Huntington's disease. It also develops Miraxion for the treatment of other central nervous system disorders, including treatment unresponsive depression. The company, formerly known as Ethical Holdings plc, was incorporated in 1989 and is headquartered in London.

DYNAVAX TECHNOLOGIES CORPORATION (DVAX)

Dynavax Technologies Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases. The company's clinical development programs are based on immunostimulatory sequences, which are short DNA sequences that enable the immune system to fight disease and control chronic inflammation. Its pipeline includes TOLAMBA, a ragweed allergy immunotherapeutic, which is in a Phase II/III clinical trial and in a supportive clinical trial in ragweed allergic children; HEPLISAV, a hepatitis B vaccine in a pivotal Phase III clinical trial; a cancer therapy in a Phase II clinical trial; and an asthma immunotherapeutic that has shown preliminary safety and pharmacology in a Phase IIa clinical trial. The company was founded in August 1996 as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax is based in Berkeley, California.

GENTIUM SPA - ADS REPRESENTS ORDINARY SHARES (GENT)

Gentium S.p.A., a biopharmaceutical company, engages in the research, development, and manufacture of drugs to treat and prevent various vascular diseases and conditions related to cancer and cancer treatments. It manufactures defibrotide to treat deep vein thrombosis, and to treat and prevent various vascular diseases with risk of thrombosis. The company also conducts Phase III clinical trials of defibrotide to treat Veno-Occlusive Disease with multiple-organ failure; and phase I/II clinical trials to treat multiple myeloma. In addition, Gentium offers urokinase, which is used to treat various vascular disorders, such as deep vein thrombosis and pulmonary embolisms; and heparin calcium, which is used for the treatment of certain types of lung, blood vessel, and heart disorders, and administration during or after certain types of surgery, such as open heart and bypass surgeries. Further, it manufactures sulglicotide, which is intended to treat peptic ulcers. Additionally, Gentium develops a formulation of the drug mesalazine to treat inflammatory bowel disease. It sells its products primarily in Italy. The company was founded in 1993 as Pharma Research S.r.L. and changed its name to Gentium S.p.A. in 2001. Gentium is based in Villa Guardia, Italy.

OPKO HEALTH INC (OPK)

Opko Health, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment and prevention of ophthalmic disorders and diseases. Its product candidates include bevasiranib sodium, which completed a Phase II clinical trial for the treatment of wet age-related macular degeneration (Wet AMD) and diabetic macular edema. The company is also developing product candidates for the treatment of Wet AMD, which target other pathways involved in the pathogenesis of Wet AMD, including hypoxia-inducible factor 1 alpha. In addition, it is developing products for the treatment of dry age-related macular degeneration and retinitis pigmentosa diseases. Opko Health has collaboration and license agreements with University of Pennsylvania, Intradigm Corporation, Pathogenics, Inc., University of Illinois, ZaBeCor Pharmaceutical Company, LLC, and University of Florida Research Foundation. The company was founded in 2006 and is based in Miami, Florida.

IDENIX PHARMACEUTICALS INC (IDIX)

Idenix Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of human viral and other infectious diseases. It primarily focuses on the treatment of infections caused by hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV). The company's HBV product candidates include telbivudine for the treatment of an inflammatory liver disease associated with chronic HBV infection; and valtorcitabine, which is in phase IIb clinical trial. Idenix also develops valopicitabine or NM283 for the treatment of HCV, as well as a product candidate from the class of compounds known as nonnucleoside reverse transcriptase inhibitors for the treatment of HIV. Its Telbivudine product candidate is in phase III clinical trial, and valopicitabine or NM283 product candidate is in phase IIb clinical trial. The company was founded in 1998 and is headquartered in Cambridge, Massachusetts. Idenix Pharmaceuticals, Inc. is a subsidiary of Novartis Pharma AG.

ACHILLION PHARMACEUTICALS INC (ACHN)

Achillion Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for infectious diseases. It focuses on the development of antivirals for the treatment of HIV infection and chronic hepatitis C; and antibacterials for the treatment of serious hospital-based bacterial infections. The company's lead drug candidate is elvucitabine, an antiviral in phase II clinical trials for the treatment of HIV infection. It also develops ACH-702, a preclinical candidate for the treatment of serious hospital-based bacterial infection; and NS4A Antagonists, a preclinical-stage program for chronic hepatitis C. The company has research collaboration with Gilead Sciences, Inc. to develop and commercialize compounds for the treatment of chronic hepatitis C. Achillion was founded in 1998 and is based in New Haven, Connecticut.

ONCOLYTICS BIOTECH INC - COMMON SHARES (ONCY)

No description available.

INTERMUNE INC (ITMN)

InterMune, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies in pulmonology and hepatology. The company markets various products, including Actimmune (interferon gamma-1b) for the treatment of severe osteopetrosis, and chronic granulomatous disease; Infergen (consensus interferon alfacon-1) for the treatment of patients with compensated liver disease with chronic hepatitis C virus infections; and Amphotec (amphotericin B cholesteryl sulfate complex for injection) for the treatment of invasive aspergillosis. In pulmonology area, InterMune develops Actimmune, a second phase III clinical trial, which is used for the treatment of patients with idiopathic pulmonary fibrosis; and interferon gamma-1b under the name Imukin. In hepatology area, it is developing once-daily Infergen in combination with ribavirin therapy for the treatment of patients suffering from chronic HCV infections; Infergen in combination with Actimmune, which is in Phase IIb clinical trial for the treatment of hepatitis C nonresponders; and PEG-Alfacon-1 that completed phase I clinical trial for the treatment of chronic HCV infections. In addition, the company evaluates Actimmune in patients with ovarian cancer in a Phase III trial. InterMune has collaboration and licensing agreements with Boehringer Ingelheim International GmbH; Maxygen Holdings, Ltd.; and Array BioPharma, Inc. The company was incorporated in 1998 and is headquartered in Brisbane, California.

THERAVANCE INC (THRX)

Theravance, Inc. engages in the discovery, development, and commercialization of small molecule medicines for respiratory disease, bacterial infections, overactive bladder, and gastrointestinal disorders. As of April 7, 2005, telavancin, the company's injectable antibiotic, was in Phase 3 clinical studies for the treatment of Gram-positive infections and in patients whose infections were due to methicillin-resistant Staphylococcus aureus in both complicated skin and skin structure infections and hospital-acquired pneumonia. Its other product candidates in development include TD-6301 for overactive bladder; TD-2749 and TD-5108 for gastrointestinal motility dysfunction; and TD-4756 for emergence from hypnosis. Theravance has various other product candidates in the identification and preclinical testing stages. The company has a collaboration agreement with GlaxoSmithKline (GSK) to develop and commercialize long acting beta2 agonist product candidates for the treatment of asthma and chronic obstructive pulmonary disease. It also has a strategic alliance with GSK. Theravance, Inc. has collaboration with Astellas Pharma, Inc. for the development and commercialization of its investigational antibiotic, telavancin. The company was co-founded by P. Roy Vagelos and George M. Whitesides in 1996. It was formerly known as Advanced Medicine, Inc. and changed its name to Theravance, Inc. in 2002. Theravance is headquartered in South San Francisco, California.

CHELSEA THERAPEUTICS INTERNATIONAL LTD (CHTP)

Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses to acquire and develop products for the treatment of various human diseases. The company develops prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease, and cancer. It also develops therapeutic agent for the treatment of neurogenic orthostatic hypotension and related conditions, and diseases. In addition, the company develops platform technologies that consist of a portfolio of molecules for the treatment of various autoimmune/inflammatory diseases, and I-3D portfolio, a dihydroorotate dehydrogenase inhibiting compound. Chelsea Therapeutics' product in development includes CH-1504, an orally available molecule for the treatment of rheumatoid arthritis, psoriasis, inflammatory bowel disease, psoriatic arthritis, and cancer. The company was incorporated in 2002 and is based in Charlotte, North Carolina.

ZALICUS INC COMMON (ZLCS)

<a href="http://www.combinatorx.com">Home Page</a>

CLEVELAND BIOLABS INC (CBLI)

CLEVELAND BIOLABS, INC. engages in the discovery, development, and commercialization of products for cancer treatment and protection of normal tissues from radiation and toxins in the United States. Its products in development include Protectans, the modified proteins of microbes that protect cells from apoptosis; and Curaxins, the small molecules that destroy tumor cells by simultaneously targeting two regulators of apoptosis. The company's lead product candidates, CBLB502 showed radioprotective efficacy as a single therapy in non-human primates; and Protectan CBLB612 provided protection in a mouse model from lethal hematopoietic-induced radiation sickness. In addition, it is developing Curaxin CBLC102, a Phase II clinical trial product, for the treatment of hormone refractory prostate cancer. CLEVELAND BIOLABS has a collaboration agreement with Cleveland Clinic Foundation to use Cleveland Clinic's research base underlying the company's therapeutic platform; strategic research partnership with Roswell Park Cancer Institute to develop its cancer and radioprotectant drug candidates; and strategic partnership with ChemBridge Corporation to access a chemical library of 214,000 compounds, and jointly manage the development and commercialization of compounds arising from selected projects. The company was founded in 2003 and is headquartered in Buffalo, New York.

ILLUMINA INC (ILMN)

Illumina, Inc. engages in the development and marketing of tools for the large-scale analysis of genetic variation and function. Its tools provide information used to improve drugs and therapies, customize diagnoses and treatment, and cure diseases. Its genotyping service product line combines the company's BeadArray technology with an automated, laboratory information management system controlled process to provide throughput identification of the common form of genetic variation, known as single nucleotide polymorphisms. The BeadArray technology combines microscopic beads and a substrate in a proprietary manufacturing process to produce arrays that can perform various assays simultaneously. This technology includes the BeadArray Reader, GoldenGate assay protocols, laboratory information management system and analytical software, fluid-handling robotics, and access to Sentrix arrays and reagent kits for analyzing genetic sequences. Illumina offers Oligator technology for the parallel synthesis of various oligonucleotides for genomics applications. The company also provides DASL, a gene expression assay, for generating gene expression profiles from RNA samples, including those containing partially degraded RNAs. It offers SNP Genotyping, gene expression profiling, scanning instrumentation, and high-throughput synthesis. Illumina has a strategic collaboration with Invitrogen Corporation to synthesize and distribute oligos. The company markets and distributes its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as to academic or private research centers in North America, Europe, Japan, Singapore, and the Pacific Rim countries. Illumina was founded by John R. Stuelpnagel and Mark Chee in 1998. The company is based in San Diego, California.

ZIOPHARM ONCOLOGY INC (ZIOP)

ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of a portfolio of in-licensed cancer drugs. It focuses primarily on the licensing and development of proprietary drug candidate families that are related to cancer therapeutics that are already on the market or in development. The company's product candidates include ZIO-101, ZIO-201, and ZIO-301, which are in phase I and/or II studies. ZIO-101, organic arsenic is in a phase I/II trial in patients with advanced myeloma, as well as a phase I trial in advanced cancers; ZIO-201, stabilized isophosphoramide mustard is in a phase I/II trial in patients with advanced sarcoma, as well as in a phase I trials in advanced cancers; and ZIO-301, an anti-cancer agent that targets mitosis like the taxanes is in a phase I trial. ZIOPHARM was founded in 2003 and is based in New York, New York.

SYNTA PHARMACEUTICALS CORP (SNTA)

Synta Pharmaceuticals Corp., a biopharmaceutical company, focuses on discovering, developing, and commercializing small molecule drugs to extend and enhance the lives of patients with severe medical conditions, including cancer and chronic inflammatory diseases. Its product pipeline primarily includes elesclomol, formerly STA-4783, which is in Phase III clinical trial for the treatment of metastatic melanoma, and about to enter Phase IIb clinical trial for the treatment of additional cancers. The company has a collaboration agreement with Glaxosmithkline for the development of elesclomol. Its other drug candidates include Apilimod (STA-5326), which is in Phase IIa clinical trial in patients with rheumatoid arthritis, as well as sponsors a Phase IIa clinical trial in patients with common variable immunodeficiency. In addition, it develops STA-9090, an Hsp90 inhibitor and STA-9584, which are in preclinical development; and Oral CRAC ion channel inhibitor program that is in the lead optimization stage for the treatment of autoimmune diseases. Synta Pharmaceuticals was founded in 2000 and is based in Lexington, Massachusetts.

THE MEDICINES COMPANY (MDCO)

The Medicines Company, a pharmaceutical company, engages in the acquisition, development, and commercialization of acute care hospital products. The company offers Angiomax, a direct thrombin inhibitor, for use as an anticoagulant in patients with unstable angina undergoing coronary angioplasty. It also develops clevelox, an intravenous drug intended for the short-term control of blood pressure in surgical patients, including patients undergoing cardiac surgery; and cangrelor, an antiplatelet agent that prevents platelet aggregation. The company markets, distributes, and sells its products to hospital management, physicians, hospital pharmacists, nurses, and other care staff in the United States, as well as through third-party distributors internationally. It has licensing agreements with Biogen Idec, Inc. and AstraZeneca AB. The company was founded in 1996 and is headquartered in Parsippany, New Jersey.

SEQUENOM INC (SQNM)

SEQUENOM, Inc., a genetics company, provides genetic analysis products that translate genomic science into superior solutions for biomedical research and molecular medicine. It primarily offers MassARRAY system that includes hardware, software, and consumable products. The MassARRAY system is a DNA analysis platform that measures the amount of genetic target material and variations therein. The system delivers data from biological samples and genetic target material that is available in trace amounts. The company offers its products primarily to pharmaceutical and biotechnology companies, laboratories, and governmental and other research institutions in North America, Europe, and Asia. It has strategic collaboration agreements with Bioscientia, Siemens Medical Solutions, and Procter &amp; Gamble Pharmaceuticals. SEQUENOM was established in 1994 and is headquartered in San Diego, California.

VIVUS INC (VVUS)

VIVUS, Inc., a pharmaceutical company, engages in the research, development, and commercialization of products to restore sexual function in women and men. Its product pipeline includes four clinical stage product candidates, including ALISTA for the treatment of female sexual arousal disorder; Testosterone-MDTS to treat hypoactive sexual desire disorder; Evamist to alleviate symptoms associated with menopause; and Avanafil, an inhibitor product candidate for the treatment of erectile dysfunction. ALISTA and Evamist are in Phase 3 trials; and Testosterone-MDTS and Avanafil are in Phase 2 trials. The company also markets MUSE, a transurethral applicator used for treating erectile dysfunction, in the United States and internationally through distribution partners. It has a development, license, and supply agreement with Tanabe Seiyaku Co., Ltd., for the development and commercialization of avanafil; and licensing agreements with Acrux Limited to develop and commercialize testosterone-MDTS and Evamist in the United States for various female health applications. VIVUS was founded by Virgil A. Place in 1991 and is headquartered in Mountain View, California.

EMERGENT BIOSOLUTIONS INC (EBS)

Emergent BioSolutions, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of immunobiotics primarily in the United States. Immunobiotics are pharmaceutical products, such as vaccines and immune globulins that assist the body's immune system to prevent diseases. The company operates in two segments, Biodefense and Commercial. The Biodefense segment develops, manufactures, and commercializes immunobiotics for use against biological agents. This segment's primary product is BioThrax, a vaccine for the prevention of anthrax infection. Its other products, which are in preclinical stage comprise Anthrax immune globulin, for post-exposure treatment of anthrax infection; Botulinum immune globulin for post-exposure treatment of illness caused by botulinum toxin; and Recombinant bivalent botulinum vaccine, a prophylaxis for illness caused by botulinum toxin. The Commercial segment develops immunobiotics for use against infectious diseases. This segment's product portfolio includes Typhoid vaccine, a single-dose vaccine in phase II clinical development; Hepatitis B therapeutic vaccine, for treating chronic carriers of hepatitis B infection, which is in phase II clinical development; and Group B streptococcus vaccine, a product in phase I clinical trial for administration to women of childbearing age for protection of the fetus and newborn babies. In addition, Emergent BioSolutions is developing a chlamydia vaccine and a meningitis B vaccine, which are in preclinical development. The company serves primarily the U.S. Department of Defense and the U.S. Department of Health and Human Services. It has collaboration agreements with U.K. Health Protection Agency for the development of a human botulinum immune globulin candidate; and with Sanofi Pasteur for the development of meningitis B vaccine candidate. The company, formerly known as BioPort Corporation, was founded in 1998 and is based in Rockville, Maryland.

ALEXION PHARMACEUTICALS INC (ALXN)

Alexion Pharmaceuticals, Inc., together with its subsidiaries, engages in the discovery and development of biologic therapeutic products for the treatment of severe diseases. It develops therapeutic products for the treatment of hematologic and cardiovascular disorders, autoimmune diseases, and cancer; and additional antibody therapeutics for other medical needs. The company primarily develops two lead product candidates, eculizumab and pexelizumab, which address specific diseases that arise when the human immune system produces inflammation in the human body. Eculizumab is in phase III clinical development for treatment of Paroxysmal Nocturnal Hemoglobinuria, a chronic hematologic disease. Pexelizumab is in clinical development for the reduction of the incidence of death, myocardial infarction or heart attack, and other complications associated with coronary artery bypass graft surgery; and for acute myocardial infarction. Alexion Pharmaceuticals has a strategic alliance with Procter and Gamble Pharmaceuticals for the development of pexelizumab. The company was co-founded by Leonard Bell, Stephen P. Squinto, Scott A. Rollins, and Joseph A. Madri in 1992. Alexion Pharmaceuticals is headquartered in Cheshire, Connecticut.

NYMOX PHARMACEUTICAL CORPORATION (NYMX)

Nymox Pharmaceutical Corporation, through its subsidiaries, engages in the research and development of products for the diagnosis and treatment of Alzheimer's disease. The company markets AlzheimAlert, a urinary test that helps physicians in the diagnosis of Alzheimer's disease. It also markets NicAlert and TobacAlert tests that use urine or saliva to detect the use of tobacco products. In addition, Nymox develops therapeutics for the treatment of Alzheimer's disease; treatments for benign prostate hyperplasia; and anti-bacterial agents for the treatment of urinary tract and other bacterial infections in humans, including a treatment for E. coli O157:H7 bacterial contamination in meat and other food and drink products. The company was founded by Paul Averback in 1989 and is based in St. Laurent, Canada.

AVI BIOPHARMA INC (AVII)

AVI BioPharma, Inc., a biopharmaceutical company, engages in the development of therapeutic products based on NEUGENE antisense technology. Its principal products in development target life-threatening diseases, including cardiovascular disease, infectious disease, and cancer. AVI's lead product candidate, Resten-NG, is a NEUGENE antisense drug for treating cardiovascular restenosis, or the re-narrowing of a coronary artery following angioplasty. In addition to targeting specific genes in the body, AVI's antiviral program uses NEUGENE antisense compounds to combat disease by targeting single–stranded RNA viruses, including West Nile virus, hepatitis C virus, dengue virus, and Ebola virus. AVI has also evaluated Avicine, a therapeutic cancer vaccine, in six clinical trials involving colorectal and pancreatic cancer; completed Phase Ib/II trials of AVI-4557 targeting drug metabolism; and evaluated Phase I trials of AVI-4126 targeting polycystic kidney disease. The company has strategic alliances with SuperGen, Inc.; Medtronic, Inc.; and Exelixis, Inc. AVI was incorporated in 1980 as Antivirals, Inc. and changed its name to AVI BioPharma, Inc. in 1998. AVI is based in Portland, Oregon.

INHIBITEX INC (INHX)

Inhibitex, Inc., a development stage company, engages in the discovery, development, and commercialization of antibody-based products for the prevention and treatment of bacterial and fungal infections in the hospital setting. The company has two products candidates in late stage clinical development, which include Veronate and Aurexis. Veronate, which is in phase III clinical development, is being developed to prevent hospital-associated infections in very low birth weight infants. Aurexis is being developed to treat, in combination with antibiotics, Staphylococcus aureus infections in hospitalized patients. Aurexis completed a phase II clinical trial in May 2005. In addition, the company has three preclinical product candidates under development, including Enterococcus monoclonal antibody for the treatment of enterococcus infections; Candida monoclonal antibody for the treatment of candida infections; and Staphylococcal vaccines for active immunity against Staphylococcal infections. Inhibitex was co-founded by Joseph M. Patti and Magnus Hook. It was incorporated in 1994 and is based in Alpharetta, Georgia.

PLURISTEM THERAPEUTICS INC (PSTI)

Per-Se Technologies, Inc. offers connective healthcare solutions to physicians and hospitals in the United States. It operates through two divisions, Physician Services and Hospital Services. The Physician Services division provides business management outsourcing services to hospital-affiliated physician practice groups, physicians groups in academic settings, and other large physician practices. Its services include clinical data collection, data input, medical coding, billing, contract management, cash collections, accounts receivable management, and reporting of metrics related to the physician practice. The division also offers a physician practice management solution that is delivered through an application service provider model. The Hospital Services division delivers electronic and Internet-based business-to-business solutions that focus on electronic processing of medical transactions, as well as complementary transactions, such as electronic remittance advices, realtime eligibility verification, and print and mail services. Its other solutions include denial management, staff scheduling solutions, and patient scheduling solutions. The company markets its products and services primarily to hospital-affiliated physician practices, physician groups in academic settings, hospitals, and integrated delivery networks. Per-Se Technologies was founded in 1985 and is headquartered in Alpharetta, Georgia.

YM BIOSCIENCES INC ORDINARY SHARES (CANADA) (YMI)

YM BioSciences, Inc., a development stage biopharmaceutical company, engages in the research and development of products primarily for the treatment of cancer. Its product candidates in the clinical stage of development include Tesmilifene, Nimotuzumab, AeroLEF, Norelin, and Radiotheracim. Tesmilifene, which is in phase III clinical trial, is a small molecule chemopotentiator for the treatment of metastatic and recurrent breast cancer. Nimotuzumab, which is in phase II clinical trial, is an antiepidermal growth factor humanized monoclonal antibody for the treatment of epithelial cancers. AeroLEF, which is in phase II clinical trials, is a proprietary formulation of both free and liposome-encapsulated fentanyl administered by pulmonary inhalation, is being developed for the treatment of severe and moderate acute pain and cancer pain. Norelin is a phase II clinical trial product for the treatment of sex-hormone dependent cancers. Radiotheracim is a radiolabelled humanized monoclonal antibody, targeting the epidermal growth factor receptor, and is being developed for the treatment of brain cancers. The company also has a portfolio of preclinical compounds shown to act as chemopotentiators while protecting normal cells. YM BioSciences has a collaborative agreement with Sanofi-Aventis to investigate the effect of combining tesmilifene and docetaxel for the treatment of women with rapidly progressing metastatic breast cancer. The company was founded in 1994 and is headquartered in Mississauga, Canada.

AMICUS THERAPEUTICS INC (FOLD)

Amicus Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule, orally-administered drugs, known as pharmacological chaperones, for the treatment of a range of human genetic diseases. The pharmacological chaperone technology involves the use of small molecules to restore biological activity in cells by binding to a misfolded protein caused by a genetic mutation. The company is targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Its lead compound includes Amigal, which is in Phase II clinical trials is used for the treatment of Fabry disease that causes kidney failure, cardiac abnormalities, and neurological complications. The company is also developing AT2101 for the treatment of Gaucher disease, which causes an enlarged liver and spleen, low levels of red blood cells and platelets, bone pain, and fractures; and AT2220 for the treatment of Pompe disease, which causes muscle weakness primarily affecting breathing, mobility, and heart function. The company has a strategic collaboration with Shire Human Genetic Therapies, Inc. to jointly develop pharmacological chaperone compounds for lysosomal storage disorders. Amicus Therapeutics was founded in 2002 and is headquartered in Cranbury, New Jersey.

INCYTE CORPORATION (INCY)

Incyte Corporation engages in the discovery and development of small molecule drugs to treat medical conditions, including the infection with human immunodeficiency virus (HIV), inflammatory disorders, cancer, and diabetes. Its primary product candidate Reverset is a nucleoside analog reverse transcriptase inhibitor for use in combination with other antiviral drugs for patients with HIV infections, and is in phase IIb clinical trials. In addition, the company's drug discovery programs underway include CCR2 Receptor Antagonist Program and Sheddase Inhibitor Program. CCR2 Receptor Antagonist Program is focused on developing antagonists to a key chemokine receptor involved in inflammation called CCR2. CCR2 is a chemokine receptor found on monocytes that controls their migration into sites of inflammation. The primary products candidate form this program is in phase IIa clinical trial in patients with rheumatoid arthritis. The Sheddase Inhibitor Program involves sheddase inhibitors that would have application in the treatment of breast cancer and other tumor types and is in phase I clinical trials. The company markets its products in the United States and in Austria, Belgium, Canada, France, Denmark, Germany, Israel, Japan, the Netherlands, Sweden, Switzerland, and the United Kingdom. Incyte has collaborative agreement with Pharmasset, Inc.; Senomyx, Inc.; Genomic Health, Inc.; Pfizer, Inc.; and Medarex, Inc. Incyte was founded in 1991 and is headquartered in Wilmington, Delaware.

EXACT SCIENCES CORPORATION (EXAS)

EXACT Sciences Corporation utilizes applied genomics to develop screening technologies for use in the detection of cancer. Certain of its technologies are offered in a commercial testing service, PreGen-Plus, developed by Laboratory Corporation of America Holdings. PreGen-Plus is a non-invasive stool-based DNA testing service for the detection of colorectal cancer in the average-risk population. EXACT Sciences was founded in 1995 and is headquartered in Marlborough, Massachusetts.

REGENERON PHARMACEUTICALS INC (REGN)

Regeneron Pharmaceuticals, Inc. engages in the discovery and development of pharmaceutical products for the treatment of human disorders and conditions. Its clinical and preclinical pipeline includes product candidates for the treatment of cancer, diseases of the eye, rheumatoid arthritis, and other inflammatory conditions like allergies, asthma, and other diseases and disorders. The company primarily focuses on the development of the VEGF Trap in oncology and eye diseases, which are in phase I clinical trails; and the IL (Interleukin)-1 Trap in various indications in, which interleukin-1 plays a role, including rheumatoid arthritis and other inflammatory conditions. VEGF TRAP is a protein-based product candidate designed to bind Vascular Endothelial Growth Factor (VEGF) and the related Placental Growth Factor, and prevent their interaction with cell surface receptors. Interleukin-1 Trap, which is in preclinical stage, is a protein-based product candidate designed to bind the interleukin-1 cytokine and prevent its interaction with cell surface receptors used for the treatment of diseases associated with inflammation in blood vessels. IL-1 Trap is in phase 2b study for its use in rheumatoid arthritis in a double blind, placebo-controlled, and multicenter trial. Regeneron's product candidates in preclinical development stage include Interleukin-4/Interleukin-13 Trap, a protein-based product candidate designed to bind both the interleukin-4 and interleukin-13, which is used for the treatment of diseases, such as asthma, allergic disorders, and other inflammatory diseases. The company also provides contract manufacturing services for the production of an intermediate for a pediatric vaccine. Regeneron has collaboration and licensing agreements with sanofi-aventis Group, Novartis Pharma AG, and The Procter &amp; Gamble Company. The company was founded by Leonard S. Schleifer in 1988. Regeneron is headquartered in Tarrytown, New York.

SEATTLE GENETICS INC (SGEN)

Seattle Genetics, Inc. develops monoclonal antibody-based therapeutic products for the treatment of cancer and immunologic diseases. The company's monoclonal antibody-based technologies include genetically engineered monoclonal antibodies, antibody-drug conjugates (ADC), and antibody-directed enzyme prodrug therapy (ADEPT), which are used to develop monoclonal antibodies that can kill target cells on their own, as well as increase the potency of monoclonal antibodies. Its product candidate, SGN-30, is in phase II clinical trials, which is used for the treatment of Hodgkin's disease and systemic anaplastic large cell lymphoma; and SGN-15 has completed a phase II clinical trial for use in the treatment of nonsmall cell lung cancer. The company's SGN-40 is in phase I clinical trials in patients with multiple myeloma. In addition, it has four product candidates in preclinical development: SGN-35, SGN-70, SGN-75, and SGN-17/19. The company is conducting preclinical development tests of SGN-35 for the treatment of hematologic malignancies, such as Hodgkin's disease and some types of nonHodgkin's lymphoma. SGN-75 is an ADC composed of an anti-CD70 monoclonal antibody. The CD70 antigen is expressed on renal cancer, nasopharyngeal carcinoma, and certain hematologic malignancies. SGN-17/19, an ADEPT product candidate, is being developed for the treatment of metastatic melanoma. The company has collaboration agreements with Genentech, Celera Genomics Group, UCB Celltech, Protein Design Labs, PSMA Development Company LLC, CuraGen, and Bayer for its ADC technology; and with Genencor for its ADEPT technology. Seattle Genetics was co-founded in 1997 by H. Perry Fell and Clay B. Siegall. The company is headquartered in Bothell, Washington.

AASTROM BIOSCIENCES INC (ASTM)

Aastrom Biosciences, Inc., a development stage company, develops patient-specific products for the repair or regeneration of human tissues, utilizing its proprietary adult stem cell technology. Its lead products include tissue repair cells (TRCs), which are a mixture of bone marrow-derived adult stem and progenitor cells, produced outside of the body or ‘ex vivo' from a small amount of bone marrow taken from the patient. The company also offers AastromReplicell System, a patented, integrated system of instrumentation and single-use consumable kits for the commercial production of human cells. Aastrom Biosciences is developing TRCs for the treatment of severe bone fractures, ischemic vascular disease, jaw reconstruction, and spine fusion. It also focuses on the utilization of TRCs in the areas of bone regeneration and vascular regeneration in limb ischemia resulting from diabetes and other diseases. The company has a strategic alliance with Musculoskeletal Transplant Foundation to develop and commercialize treatments for the regeneration of tissues, such as bone and cartilage. Aastrom Biosciences was incorporated in 1989 and is headquartered in Ann Arbor, Michigan.

PROLOR BIOTECH INC (PBTH)

PROLOR Biotech, Inc., a development stage biopharmaceutical company, develops proprietary versions of already-approved therapeutic proteins. The companyÂ's technology, Carboxyl Terminal Peptide technology could be attached to an array of existing therapeutic proteins, stabilizing the therapeutic protein in the bloodstream and extending its life span without additional toxicity or loss of desired biological activity. Its products under development include Human Growth Hormone, which is used for the long-term treatment of children and adults with growth failure due to inadequate secretion of endogenous growth hormone; Erythropoietin for individuals with chronic kidney failure, chemotherapy patients, and HIV/AIDS patients on AZT, as well as for patients who may require a blood transfusion or undergo surgery where blood loss is expected; and Interferon ß that is used to reduce the frequency and severity of relapses afflicting people suffering from multiple sclerosis, as well as Factor VIIa, Factor IX; Anti-Obesity Peptide; and Glucagon-Like Peptide-1. The company was formerly known as Modigene Inc. and changed its name to PROLOR Biotech, Inc. in June 2009. PROLOR Biotech, Inc. was founded in 2001 and is based in Nes-Ziona, Israel.

SANGAMO BIOSCIENCES INC (SGMO)

Sangamo Biosciences, Inc. engages in the research, development, and commercialization of DNA binding proteins for the therapeutic regulation and modification of disease-associated genes. The company's gene regulation technology platform is enabled by the engineering of a class of transcription factors, known as zinc finger DNA-binding proteins (ZFPs). The applications of the company's technology include pharmaceutical discovery, development of human therapeutics, and plant agriculture. It has also initiated preclinical animal studies of ZFP therapeutics in congestive heart failure, nerve regeneration, and neuropathic pain; and has research-stage programs in human immunodeficiency virus, sickle cell anemia, X-linked severe combined immunodeficiency, Wiskott Aldrich Syndrome, age-related macular degeneration, and cancer immunotherapy. The company has strategic partnership with Edwards Lifesciences Corporation. Sangamo BioSciences has a research collaboration agreement with Pfizer, Inc. to develop cell lines for enhanced protein production. Sangamo Biosciences was founded in 1995 by Edward Lanphier. The company is headquartered in Richmond, California.

CURIS INC (CRIS)

Curis, Inc., a therapeutic drug development company, focuses on the discovery and development of products that modulate key regulatory signaling pathways controlling the repair and regeneration of human tissues and organs. Its product development approach involves using small molecules, proteins, or antibodies to modulate these regulatory signaling pathways. Curis uses this product development approach to produce various drug product candidates in the fields of cancer, kidney disease, neurological disorders, hair growth, and cardiovascular disease. The company is developing its product candidate programs in various signaling pathways, including the Hedgehog and Bone Morphogenetic Protein pathways. Its lead product candidate is a topical therapy for the treatment of basal cell carcinoma and is under development in collaboration with Genentech, Inc. The company has strategic collaborations with Genentech and Wyeth Pharmaceuticals to develop therapeutics, which modulate the signaling of the Hedgehog pathway; an additional collaboration with Genentech to develop therapeutics that modulate an undisclosed signaling pathway that plays an important role in cell proliferation; and a research and development agreement with Procter &amp; Gamble Pharmaceuticals U.K. Limited to evaluate and develop treatments for hair growth regulation utilizing Curis' Hedgehog agonist technology. Curis is headquartered in Cambridge, Massachusetts.

PROTALIX BIOTHERAPEUTICS INC (PLX)

Protalix BioTherapeutics, Inc., a development stage company, engages in developing and producing recombinant therapeutic proteins that are expressed through its plant cell system in the United States. Its principal product candidate, prGCD, is a proprietary plant cell expressed recombinant Glucocerebrosidase enzyme-based protein for the treatment of Gaucher Disease. The company is also developing PRX-102, a proprietary alpha Galactosidase enzyme for the treatment of Fabry disease, a genetic lysosomal storage disorder in humans, the symptoms of which involve the accumulation of lipids in the cells of the kidneys, heart, and other organs; and PRX-111, a human fertility hormone targeted at the infertility market. In addition, it is developing a proprietary plant-based acetylcholinestrase and its molecular variants for use in various therapeutic and prophylactic indications, including a Biodefense program; and an oral platform for delivering active recombinant proteins systematically through enteral administration through the oral administration of transgenic plant cells. Protalix BioTherapeutics has strategic collaboration with Teva Pharmaceutical Industries, Ltd. for the development and manufacturing of two proteins using the company's plant cell expression system; and Yeda Research and Development Company Limited to design Glucocerebrosidase for the treatment of Gaucher Disease, as well as a licensing agreement with Icon Genetics AG to license Icon's amplification technology for utilization in the expression of its products. The company was founded in 1993 and is based in Carmiel, Israel.

RAPTOR PHARMACEUTICAL CORP (RPTP)

Raptor Pharmaceuticals Corp. operates as a development stage biotechnology company in the United States. The company engages in the discovery, research, and preclinical development of drug candidates and drug-targeting platforms for the treatment of various brain disorders and neurodegenerative diseases, genetic disorders, and cancer through the proprietary use of receptor-associated proteins and mesoderm development proteins. Its clinical-stage products include DR Cysteamine, which is in Phase IIb clinical trail for the treatment of nephropathic cystinosis or cystinosis; and in Phase IIa clinical trail for the treatment of non-alcoholic steatohepatitis. The company also develops Convivia, a Phase IIa clinical trail product for the treatment of aldehyde dehydrogenase or ALDH2 deficiency; DR Cysteamine, which is in Phase II clinical trail for the treatment of HuntingtonÂ's Disease; and Tezampanel and NGX 426 that is in Phase II clinical trail for the treatment of migraine, acute pain, and chronic pain. In addition, its preclinical development products comprise HepTide for the treatment of Hepatocellular Carcinoma and Hepatitis C; WntTide for the treatment of breast cancer; and NeuroTrans for the treatment of neurodegenerative diseases. The company has collaboration agreements with the University of California, San Diego for a clinical study of DR Cysteamine in juvenile patients with Non-Alcoholic Steatohepatitis and to study DR Cysteamine in patients with cystinosis. Raptor Pharmaceuticals Corp was founded in 2005 and is based in Novato, California.

SERACARE LIFE SCIENCES INC (SRLS)

SeraCare Life Sciences, Inc. provides products and services to facilitate the discovery, development, and production of human and animal diagnostics and therapeutics primarily in the United States, Europe, and Asia. It operates through two segments, Diagnostic & Biopharmaceutical Products and BioServices. The Diagnostic & Biopharmaceutical Products segment manufactures and sells diagnostic control and panel products for clinical labs testing for infectious diseases; and for employee training and competency assessment programs. It offers approximately 100 control and panel products for infectious diseases, including HIV, hepatitis A, HBV, HCV, WNV, Chagas, and HPV. This segment also provides reagents and bioprocessing products, such as diagnostic intermediates, cell culture additives and media, therapeutic grade albumin, and purified viable human cells used in the research, development, and manufacturing of human and animal diagnostics, therapeutics, and vaccines. The BioServices segment provides biobanking, sample processing, and testing services. It also offers research and clinical trial support services, including assisting with collecting, cataloging, processing, transporting, cryopreservation, storing, and tracking of samples collected during research studies and clinical trials. In addition, this segment provides technical support and training to collaborators and investigators on issues related to specimen processing and handling. SeraCare Life Sciences' customers include in vitro diagnostic manufacturers; hospital-based, independent, and public health labs; blood banks; government and regulatory agencies; and organizations involved in the discovery, development, and commercial production of human and animal therapeutics and vaccines, including pharmaceutical and biotechnology companies, veterinary companies, and academic and government research organizations. The company was founded in 1984 and is headquartered in Milford, Massachusetts.

AETERNA ZENTARIS INC (AEZS)

AEterna Zentaris, Inc., a biopharmaceutical company, engages in the discovery, development, and marketing of oncology and endocrine therapy focused drugs. Its product line leverages five different therapeutic approaches such as: luteinizing hormone releasing hormone (LHRH) antagonists, signal transduction inhibitors, cytotoxic conjugates and cytotoxics, tubulin inhibitors/vascular targeting agents, and growth hormone modulators. The company markets cetrorelix for in vitro fertilization and Impavido for black fever and parasitic skin diseases. Its other products, which are in various stages of clinical development include D-63153, a linear decapeptide sequence; Teverelix; Perifosine, an alkylphosphocholine compound; Erucylphosphocholine, an analog of perifosine, for intravenous administration; Miltefosine; PI3K Inhibitors; Lobaplatin, a platinum derivative; Disorazol E for the treatment of cancer; Neovastat, an oral antiangiogenic product; RC-3095 a hormone-like peptide; GH-RH Antagonists; and Ghrelin Receptor Antagonists. The company, through Atrium Biotechnologies, Inc., develops and markets active ingredients, specialty fine chemicals, cosmetic, and nutritional products for the cosmetics, chemical, pharmaceutical, and nutritional industries. AEterna Zentaris has strategic alliances with Serono International S.A.; Solvay Pharmaceuticals Bv.; Shionogi &amp; Co., Ltd.; Nippon Kayaku Co., Ltd.; German Remedies; Spectrum Pharmaceuticals, Inc.; Ardana Bioscience, Ltd.; Grupo Ferrer; LG Life Sciences; Mayne Pharma; and Ardana Bioscience, Ltd. The company was founded in 1990. It was formerly known as 171162 Canada, Inc. and changed its name to Les Laboratoires Aeterna, Inc. in 1991. Further, the company changed its name to AEterna Laboratories, Inc. in 1997 and to AEterna Zentaris, Inc. in 2004. AEterna Zentaris is headquartered in Quebec City, Canada.

TARGACEPT INC (TRGT)

Targacept, Inc., a biopharmaceutical company, engages in the design, discovery, and development of drugs for the treatment of multiple diseases and disorders of the central nervous system. As of December 31, 2006, the company had four clinical-stage product candidates and three preclinical product candidates in its product portfolio. Its product candidates are in development as treatments for target indications in three therapeutic areas: cognitive impairment, depression and anxiety, and pain. The company principally offers Inversine, which is approved for marketing for the management of moderately severe to severe essential hypertension, a high blood pressure disorder. Its product candidates include TC-1734, a Phase II clinical trial completed product for the treatment of Alzheimer's disease, cognitive deficits in schizophrenia, and other conditions characterized by cognitive impairment, such as attention deficit hyperactivity disorder, age associated memory impairment, and mild cognitive impairment. Targacept's product candidates also include TC-2696 for acute post-operative pain; mecamylamine hydrochloride, the active ingredient in Inversine; and TC-5214, one of the enantiomers of mecamylamine hydrochloride; TC-2216, a phase I product for depression and anxiety disorders; and TC-5619 for various conditions, such as schizophrenia, cognitive impairment, and inflammation. The company has a collaborative research and license agreement with AstraZeneca AB for development and commercialization of TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia, and other cognitive disorders. Targacept was founded in 1997 and is based in Winston-Salem, North Carolina.

PROGENICS PHARMACEUTICALS INC (PGNX)

Progenics Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products to treat the unmet medical needs of patients with debilitating conditions and life-threatening diseases. It offers products for the areas of symptom management and supportive care, and the treatment of HIV infection and cancer. The company's methylnaltrexone is designed to reverse the side effects of opioid pain medications while maintaining pain relief and also for the management of post-operative bowel dysfunction caused by endogenous, or naturally occurring, opioids. The company is developing viral-entry inhibitors in the area of HIV infection, including PRO 140, a humanized monoclonal antibody targeting the HIV coreceptor CCR5; PRO 542, a genetically engineered molecule designed to neutralize HIV by preventing it from attaching to the CD4 receptor on the surface of immune system cells; ProVax for the prevention of HIV infection or as a therapeutic treatment for HIV-positive individuals. The company, in collaboration with Cytogen Corporation, is developing immunotherapies for prostate cancer, including a human monoclonal antibody directed against prostate-specific membrane antigen, a protein found on the surface of prostate cancer cells. It is also developing vaccines designed to stimulate an immune response to PSMA. The company is also developing a cancer vaccine, GMK, which is in phase 3 clinical trials for the treatment of malignant melanoma. Progenics Pharmaceuticals has agreement with Wyeth Pharmaceuticals for the joint development and commercialization of methylnaltrexone for the treatment of opioid-induced side effects, including constipation and post-operative bowel dysfunction. The company was founded by Paul J. Maddon. Progenics Pharmaceuticals was incorporated in 1986 and is based in Tarrytown, New York.

BIOMIMETIC THERAPEUTICS INC (BMTI)

BioMimetic Therapeutics, Inc. engages in the development and commercialization of bio-active drug-device combination products for healing musculoskeletal injuries and diseases that include periodontal, orthopedic, spine, and sports injury applications. It primarily engages in the development of the treatment for bone loss associated with advanced periodontal disease, and repair and regeneration of orthopedic tissues, including bone, cartilage, and ligaments or tendons. The company's GEM 21S Growth-factor Enhanced Matrix (GEM) is a synthetic regeneration system that combines a recombinant human platelet-derived growth factor with a synthetic bone matrix called beta-tricalcium phosphate in order to treat periodontal bone defects and gum tissue recession associated with periodontal diseases. It also develops GEM product candidates in the field of orthopedics, including bone, tendon, ligament, and cartilage applications. The company also develops GEM OS1 for the treatment of open fractures; GEM OS2 for the treatment of closed fractures; and other GEM OS product candidates for the areas of the skeletons, such as the vertebral bodies of the spine in osteoporotic individuals that are susceptible to fracture, and where stimulation of new bone formation could have a prophylactic therapeutic benefits. In addition, the company's pre-clinical development products include GEM C and GEM LT, which are used for various sports injuries, including those requiring cartilage, ligament, and tendon repair. Further, it offers GEM ONJ for treating osteonecrosis of the jaws. BioMimetic Therapeutics has a partnership with Luitpold Pharmaceuticals, Inc. for the marketing and distribution of GEM 21S worldwide. The company was founded in 1999. It was formerly known as BioMimetic Pharmaceuticals, Inc. and company changed its name to BioMimetic Therapeutics, Inc. in 2005. BioMimetic Therapeutics is headquartered in Franklin, Tennessee.

ARENA PHARMACEUTICALS INC (ARNA)

Arena Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs in the therapeutic areas of metabolic, cardiovascular, inflammatory, and central nervous system diseases. The company is developing a pipeline of compounds that act on drug targets called G protein-coupled receptors, using its proprietary technologies, including Constitutively Activated Receptor Technology and Melanophore. Arena's products principally include APD356, a Phase II clinical trial 5-HT2C serotonin receptor agonist, which would be used for the treatment of obesity; and APD125, a Phase I clinical trial product, for the treatment of insomnia. Arena Pharmaceuticals has research collaborations with Ortho-McNeil Pharmaceutical, Inc. and Merck &amp; Co., Inc. for products in various indications. The company was co-founded by Dominic P. Behan and Jack Lief. Arena Pharmaceuticals was incorporated in 1997 and is based in San Diego, California.

AVEO PHARMACEUTICALS INC (AVEO)

AVEO Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of cancer therapeutics. The companyÂ's lead product candidate, Tivozanib (AV-951), is a novel, highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2, and 3. It is also leading the clinical development of AV-299, which includes conducting multiple Phase I clinical trials and preparing for the conduct of multiple Phase II clinical trials. The companyÂ's product candidate in preclinical development is AV-203, a potent ErbB3 antibody that has demonstrated efficacy in vivo. It has strategic partnerships with OSI Pharmaceuticals, Inc., Merck, and Biogen Idec, Inc. AVEO Pharmaceuticals was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. The company was founded in 2001 and is based in Cambridge, Massachusetts.

GEN-PROBE INCORPORATED (GPRO)

Gen-Probe Incorporated engages in the development, manufacture, and marketing of nucleic acid probe-based products for the clinical diagnosis of human diseases, and for the screening of donated human blood. It markets a portfolio of products that use company's technologies to detect various infectious microorganisms, including those causing sexually transmitted diseases, tuberculosis, strep throat, pneumonia, and fungal infections. The company also offers blood-screening assays for the simultaneous detection of human immunodeficiency virus (type 1), hepatitis C virus, and hepatitis B virus presence. In addition, Gen-Probe offers TIGRIS DTS instrument that is used for investigational use in blood screening applications in the United States. The company markets its products to various customers, such as reference laboratories, public health laboratories, and hospitals in North America, Europe, and Japan. It has strategic alliance agreements with Chiron Corporation and Bayer Corporation, as well as has licensing agreements with Corixa Corporation, AdnaGen AG, DiagnoCure, Vysis, Inc., and Organon Teknika B.V. The company also has a collaboration agreement with GE Infrastructure Water and Process Technologies, and Millipore Corp. for developing, manufacturing, and commercializing nucleic acid testing technologies. Gen-Probe Incorporated was founded by David E. Kohne, Thomas H. Adams, and Howard C. Birndorf in 1983. The company is headquartered in San Diego, California.

REPLIGEN CORPORATION (RGEN)

Repligen Corporation develops novel therapeutics for the treatment of diseases of the central nervous system. It sells Protein A products, which are used in the production of monoclonal antibodies and SecreFlo, a synthetic form of the hormone secretin, which is used as an aid in the diagnosis of certain pancreatic disorders. The company sells Protein A products to chromatography companies, diagnostics companies, biopharmaceutical companies, and laboratory researchers primarily through value-added resellers and distributors in the United States and internationally. It markets SecreFlo directly to gastroenterologists in the United States. The company also conducts drug development programs for diseases, such as schizophrenia, obsessive-compulsive disorder, bipolar disorder, and neurodegeneration. Repligen has a development agreement with the Stanley Medical Research Institute for a Phase 2 clinical trial of uridine in bipolar depression. The company was founded in 1981 and is based in Waltham, Massachusetts.

GENOMIC HEALTH INC (GHDX)

Genomic Health, Inc., a life science company, engages in the development and commercialization of genomic-based clinical diagnostic tests for cancer in the United States. Its clinical diagnostic tests for cancer enable physicians and patients to make individualized treatment decisions. The company's genomic test, Oncotype DX, is a clinical laboratory test that predicts the likelihood of cancer recurrence, the likelihood of patient survival within 10 years of diagnosis, and the likelihood of chemotherapy benefit. This test is focused on patients with early stage, node negative, or N&#8722;, and estrogen receptor positive, or ER+, breast cancer. Genomic Health is in the early development phase of investigating additional genes and gene combinations that may add to the predictive power of Oncotype DX; and in the early development phase for a product to predict the likelihood of recurrence and chemotherapy benefit in N&#8722; and ER&#8722; breast cancer patients, as well as taxane benefit. In addition, the company has products in various stages of development for other cancers, including colon cancer, prostate cancer, renal cell cancer, non-small cell lung cancer, and melanoma. Further, it is in the early development phase to develop tests to predict the likelihood of response to the EGFR inhibitor class of drugs. Genomic Health has a collaborative agreement with Aventis, Inc. to investigate the ability of gene expression in fixed-paraffin-embedded tissues to predict the likelihood of response to adjuvant chemotherapy, including Taxotere, in patients with early breast cancer and zero to three involved lymph nodes. The company was founded in 2000 and is based in Redwood City, California.

MANNKIND CORPORATION (MNKD)

MannKind Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic products for diseases, such as diabetes and cancer. It commenced phase three clinical trials in Europe of its lead product, the Technosphere insulin system, to treat diabetes. This therapy consists of a dry powder Technosphere formulation of insulin that is inhaled into the deep lung using MedTone inhaler. Its technology is based on a class of organic molecules that are designed to self-assemble into small particles onto which drug molecules can be loaded. The company was incorporated in 1991 as Pharmaceutical Discovery Corporation and changed its name to MannKind Corporation in 2001. MannKind Corporation is headquartered in Valencia, California.

GENETIC TECHNOLOGIES LTD - AMERICAN DEPOSITARY SHARES REPRESENTING 30 ORDINARY SHARES (GENE)

Genetic Technologies Limited operates as a life science company specializing in genetics and genomics. The company owns and out-licenses a series of patents covering the use of ‘non-coding' DNA. It also offers a range of genetic testing services covering humans, animals, and plants. The company's services comprise human diagnostics, including testing of predisposition to disease, profiling, and forensic, as well as personalized diagnostics; animal diagnostics services that include tests for parentage, predisposition to diseases, traits, and the maintenance of stud books; and plant DNA testing services that primarily include high throughput extraction of plasmid, high throughput DNA sequencing, high throughput genotyping, marker discovery, and high volume variety identification for plants. It also engages in the research and development in the areas of genetics and related fields. The company was incorporated in 1987 as Concord Mining N.L. and changed its name to Duketon Goldfields N.L. in 1995. Later, it changed its name to Genetic Technologies Limited in 2000. The company is based in Fitzroy, Australia.

COMPUGEN LTD - ORDINARY SHARES (CGEN)

Compugen, Ltd. develops platforms, discovery engines, and related technologies that enable the discovery and analysis of genes and gene-based products, as well as mRNAs and proteins. Its platforms comprise LEADS computational biology platform, which analyzes genomic and expressed sequence data to enable discovery of genes, mRNAs, and proteins; and discovery engines that enable its researchers to identify proteins and mRNAs with predetermined properties for therapeutic and diagnostic development. The company initiates the predictive modeling of alternative splicing, antisense, and the RNA editing that provides the basis for understandings of additional biological phenomena. Compugen has an early stage in-house pipeline consisting of selected therapeutic protein candidates discovered by the company; and additional discoveries that are out-licensed for development. It also focuses on novel splice variants of known and validated therapeutic proteins, as well as novel diagnostic markers. These novel proteins constitute an intellectual property portfolio, which includes novel prostate specific antigens, a novel vascular endothelial growth factor, a splice variant of CD40, and other proteins. The company operates primarily in the United States, Israel, Europe, and the Far East. Compugen has a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development and commercialization of immunoassay diagnostic markers. The company was established in 1993 and is headquartered in Tel Aviv, Israel.

BIOMARIN PHARMACEUTICAL INC (BMRN)

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of biopharmaceuticals and therapeutics for serious diseases and medical conditions. Its product portfolio comprises three approved products and various investigational product candidates. The company offers Aldurazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis I, a progressive and debilitating life-threatening genetic disease that frequently results in death during childhood or early adulthood; Naglazyme, an enzyme replacement therapy for the treatment of mucopolysaccharidosis VI, an inherited, life-threatening lysosomal storage disorder; and Orapred, a drug primarily used to treat asthma exacerbations in children and other inflammatory conditions. BioMarin is also developing additional proprietary formulations of Orapred, including Orapred ODT (orally disintegrating tablets), which is under U.S. FDA review. In addition, the company is developing various other product candidates, including Phenoptin, a proprietary synthetic oral form of tetrahydrobiopterin for the treatment of moderate to mild forms of phenylketonuria (PKU); Phenylase, a preclinical-stage enzyme substitution therapy for the treatment of the more severe form of PKU; and 6R-BH4 for vascular dysfunction. BioMarin has a joint venture, BioMarin/Genzyme LLC, with Genzyme Corporation for the development and commercialization of Aldurazyme, as well as a strategic business partnership with Daiichi Suntory Pharma Co., Ltd. and Serono for Phenoptin, Phenylase and 6R-BH4 for cardiovascular indications. The company was founded in 1996 and is headquartered in Novato, California.

AMYLIN PHARMACEUTICALS INC (AMLN)

Amylin Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of drug candidates for the treatment of diabetes, obesity, and cardiovascular disease. Its primary drug candidates include exenatide and SYMLIN, which have completed phase III clinical trials for the treatment of diabetes. The company is developing exenatide for the treatment of type II diabetes, as well as studying a sustained release formulation of exenatide. Amylin Pharmaceuticals is developing SYMLIN for the treatment of patients with type I diabetes and insulin-using patients with type II diabetes. SYMLIN injection received the United States Food and Drug Administration approval for use in conjunction with insulin to treat diabetes. The company also has two early stage development programs for the treatment of obesity, including a phase II program for AC137 and AC162352 that completed a Phase I study. In addition, it is studying AC2592, which is in a phase II program for the treatment of patients with severe congestive heart failure, as well as AC3056, which is in phase I program for the treatment of atherosclerosis-related cardiovascular disease. Amylin Pharmaceuticals has a collaboration agreement with Eli Lilly and Company for the development and commercialization of exenatide, including sustained release formulations of that compound. It also has a collaboration agreement with Alkermes, Inc. for the development, manufacture, and commercialization of an injectable sustained-release formulation of exenatide. The company was co-founded by Howard E. Greene, Jr in 1987. Amylin Pharmaceuticals is headquartered in San Diego, California.

3SBIO INC - AMERICAN DEPOSITARY SHARES EACH REPRESENTING SEVEN ORDINARY SHARES (SSRX)

3SBio, Inc., a biotechnology company, focuses on the research, development, manufacture, and marketing of biopharmaceutical products primarily in the People's Republic of China. Its product candidates are designed to address unmet medical needs in nephrology, oncology, supportive cancer care, inflammation, and infectious diseases. The company's principal product, EPIAO is an injectable recombinant human erythropoietin that is used to stimulate the production of red blood cells in patients with anemia and to reduce the need for blood transfusions. It also offers TPIAO, a recombinant human thrombopoietin indicated for the treatment of chemotherapy-induced thrombocytopenia, a deficiency of platelets. In addition, the company markets two protein-based therapeutics, Intefen, a recombinant interferon alpha-2a product indicated for the treatment of carcinoma of the lymphatic or hematopoietic system and viral infectious diseases; and Inleusin, a recombinant human interleukin-2 product indicated for the treatment of renal cell carcinoma, metastatic melanoma, thoratic fluid build-up caused by cancer, and tuberculosis. Further, the company's product pipeline includes various protein-based therapeutics, including NuPIAO, a second-generation EPIAO product candidate; TPIAO for the treatment of idiopathic thrombocytopenic purpura; NuLeusin, a next-generation Inleusin product candidate; a human papilloma virus vaccine for the prevention of cervical cancer; and an anti-TNF humanized monoclonal antibody product candidate for the treatment of rheumatoid arthritis and other autoimmune diseases. 3SBio sells its products through a network of distributors to healthcare providers, including hospitals, clinics, and dialysis centers. It also markets its products through distribution agreements with local agents in various developing countries. The company was founded in 1993 and is headquartered in Shenyang, the People's Republic of China.

INTEGRA LIFESCIENCES HOLDINGS CORPORATION (IART)

Integra LifeSciences Holdings Corporation engages in the development, manufacture, and marketing of medical devices for use in neuro-trauma, neurosurgery, reconstructive surgery, and general surgery. Its product groups include monitoring products, implants, instruments, and private label products. The company's monitoring products include intracranial pressure (ICP) monitoring systems, cerebral blood flow and ICP systems, oxygen monitoring systems, cranial access and cerebrospinal fluid drainage systems, epilepsy monitoring electrodes, and electroencephalogram, evoked potential, and electromyography electrodes, as well as disposables and other supplies. Its implants include absorbable collagen products, skin replacement and engineered wound dressings, hydrocephalus management products, peripheral nerves repair and protection products, hydrocephalus management, small bone and joint fixation devices and instruments, and hemodynamic shunts. The company's instruments include ultrasonic aspirator, cranial stabilization and positioning systems, halo retractor system, electro-surgery generators, neurosurgical and spinal instruments, reconstructive and plastic surgery instruments, harvesting and conditioning skin grafts devices, and spinal specialties. Integra LifeSciences sells its products primarily through catalogs and telemarketing to neurologists, hospitals, sleep clinics, and other physicians. The company also distributes various disposables and supplies, including surface electrodes, needle electrodes, recording transducers and stimulators, and respiratory sensors. Integra LifeSciences Holdings was founded in 1989 and is based in Plainsboro, New Jersey.

BIOGEN IDEC INC (BIIB)

Biogen Idec, Inc. engages in the development, manufacture, and commercialization of novel therapies worldwide. It offers AVONEX, RITUXAN, TYSABRI, ZEVALIN, and AMEVIVE products. The company's AVONEX is approved for the treatment of relapsing forms of multiple sclerosis; RITUXAN is used in the treatment of certain B-cell non-Hodgkin's lymphomas (NHL) or B-cell NHLs; TYSABRI is approved to treat relapsing forms of MS to reduce the frequency of clinical relapses; ZEVALIN used in the treatment of cancer; and AMEVIVE treats adult patients with moderate-to-severe chronic plaque psoriasis. Biogen Idec has collaborations with Genentech, Inc.; Vernalis plc; Elan Corporation, plc; Fumapharm AG; ImmunoGen, Inc.; Sunesis Pharmaceuticals, Inc.; Cellectis SA; and Zenyaku Kogyo Co., Ltd. The company was founded in 1985. It was formerly known as IDEC Pharmaceuticals Corporation and changed its name to Biogen Idec, Inc. in 2003. Biogen Idec is headquartered in Cambridge, Massachusetts.

CHINA BIOLOGIC PRODUCTS INC (CBPO)

China Biologic Products, Inc., a biopharmaceutical company, engages in the research, development, production, and manufacture of plasma-based pharmaceutical products in the People's Republic of China. It offers Human Albumin for the treatment of shock caused by blood loss trauma or burn; raised intracranial pressure caused by hydrocephalus or trauma; oedema or ascites caused by hepatocirrhosis and nephropathy; prevention and cure of low-density-lipoproteinemia; and Neonatal hyperbilirubinemia. The company also provides Human Hepatitis B Immunoglobulin for the prevention of measles and contagious hepatitis; Human Immunoglobulin and Human Immunoglobulin for Intravenous Injection for original immunoglobulin deficiency, secondary immunoglobulin deficiency, and auto-immune deficiency diseases; and Thymopolypeptides Injection as a cure for various original and secondary T-cell deficiency syndromes, auto-immune deficiency diseases, and various cell immunity deficiency diseases, as well as assists in the treatment for tumors. In addition, it offers Human Rabies Immunoglobulin for passive immunity from bites or claws by rabies, or other infected animals; and Human Tetanus Immunoglobulin for the prevention and therapy of tetanus. The company’s products under development include Human Prothrombin Complex Concentrate, Human Coagulation Factor VIII, Human Hepatitis B Immunoglobulin (PH4) for intravenous injection, Human Fibrinogen, Varicella Hyperimmune Globulins, and Human Immunoglobulin for intravenous injection. It sells its products primarily to hospitals and inoculation centers through distributors. The company was founded in 1971 and is based in Taian City, the People's Republic of China.

PSIVIDA CORP (PSDV)

pSivida Limited, through its subsidiaries, engages in the development and commercialization of nanostructured porous silicon, called as BioSilicon for multiple potential applications in animal and human healthcare. BioSilicon functions as a honeycomb structure to retain drugs within the cells and used as a platform technology across various medical applications, including orthopedics, tissue culturing and tissue scaffolds, gene delivery, neural interfacing, and specialized drug delivery. The company develops BrachySil, an injectable BioSilicon structure, which carries 32-phosphorus, a radioactive isotope. It primarily operates in the United Kingdom, Australia, and Singapore. pSivida was founded in 1987 and is headquartered in Perth, Australia.

MEDIVATION INC (MDVN)

Medivation, Inc., a biopharmaceutical company, engages in the acquisition, research, and development of various medical technologies. It develops small molecule drugs for the treatment of Alzheimer's disease, Huntington's disease, and Hormone-Refractory Prostate Cancer. The company develops Dimebon for the treatment of Alzheimer's disease, which is in controlled Phase 2 efficacy study; Dimebon for the treatment of Huntington's disease, which is in a Phase 1-2a study; and proprietary small molecule MDV3100 for Hormone-Refractory Prostate Cancer. The company was founded in 2003 and is based in San Francisco, California.

ORCHID CELLMARK INC (ORCH)

Orchid Cellmark, Inc. provides deoxyribonucleic acid (DNA) testing services that generate genetic profile information by analyzing an organism's unique genetic identity. The company focuses on DNA testing for human identity, as well as for animal and agricultural applications. In the human identity area, it provides DNA testing services for forensic, family relationship, and security applications. In the animal and agriculture field, the company provides DNA testing services for food safety and selective trait breeding. Orchid Cellmark conducts forensic DNA testing primarily for government agencies; family relationship testing services to both government agencies and private individuals; security DNA testing services to government agencies, commercial companies, and private individuals; and animal and agriculture DNA testing services for government agencies and commercial companies. It markets its services to customers based in North America and Europe. The company was organized in 1995 and was formerly known as Orchid Biocomputer, Inc. and changed its name to Orchid Biosciences, Inc. Subsequently, it changed it name to Orchid Cellmark, Inc. in June 2005. Orchid Cellmark is headquartered in Princeton, New Jersey.

ALKERMES INC (ALKS)

Alkermes, Inc. develops pharmaceutical products based on drug delivery technologies. The company's commercial product, Risperdal Consta, is an antipsychotic medication approved for use in schizophrenia and is marketed worldwide. Its product candidate under development, Vivitrex, is a once-a-month injection for the treatment of alcohol and opioid dependence. The company has a pipeline of extended-release injectable and pulmonary drug products based on its proprietary technologies, ProLease and Medisorb, as well as inhaled drug products based on AIR technology. The company has collaborations with Cephalon, Inc., Janssen-Cilag, Eli Lilly and Company, Serono S.A., and Amylin Pharmaceutical, Inc. Alkermes was founded in 1987 and is headquartered in Cambridge, Massachusetts.

HALOZYME THERAPEUTICS INC (HALO)

Halozyme Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of products based on the extracellular matrix for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Its Enhanze Technology is a novel drug delivery platform, which is designed to increase the absorption and dispersion of biologics. The company has partnership with Roche to apply Enhanze Technology to Roche's biological therapeutic compounds for up to 13 targets. In addition, Halozyme holds Food and Drug Administration approval for two products: Cumulase and HYLENEX, for use as an adjuvant to increase the absorption and dispersion of other injected drugs and fluids. The company has partnership with Baxter Healthcare Corporation for HYLENEX. Halozyme also develops various enzymes. The company was founded in 1998 and is based in San Diego, California.

TRANSCEPT PHARMACEUTICALS INC (TSPT)

Transcept Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of proprietary products that address therapeutic needs in the field of neuroscience. Its lead product candidate, Intermezzo, a sublingual low dose formulation of zolpidem used for sleep aid has completed Phase III clinical trial. The company is headquartered in Point Richmond, California.

RESPONSE GENETICS INC (RGDX)

Response Genetics, Inc. engages in the research and development of pharmacogenomic diagnostic tests for the treatment of cancer. It offers customizable menu of fee-based pharmacogenomics services, which support clinical trials that identify patient biomarkers. The company also provides comprehensive reports on relative gene expression calculations from RT-PCR reactions using its validated database. In addition, Response Genetics conducts research for various academic institutions, including the University of Southern California. It has a collaboration agreement with Roche Diagnostics to develop new assays to test for key biomarkers. The company was founded in 1999. It was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in 2000. Response Genetics is based in Los Angeles, California.

ARRAY BIOPHARMA INC (ARRY)

Array BioPharma, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs to treat debilitating and life-threatening diseases. The company's drug development pipeline primarily focuses on the treatment of cancer and inflammatory disease, and includes drugs that regulate targets in therapeutically important disease pathways. It offers ARRY-142886 (AZD6244)/MEK, which is in the Phase Ib clinical development, for the treatment of cancer. The company also provides ARRY-334543, ErbB-2/EGFR Inhibitors, and ErbB-2 Inhibitors that are in preclinical models of human cancer. It has collaborations with Amgen; AstraZeneca; Elan; Eli Lilly and Company; Genentech, Inc.; Hoffman-La Roche, Inc.; ICOS Corporation; InterMune, Inc.; Japan Tobacco, Inc.; Procter &amp; Gamble Pharmaceuticals; QLT, Inc.; Ono Pharmaceutical Co., Ltd.; and Takeda Pharmaceutical Company, Ltd. Array was founded in 1998 and is headquartered in Boulder, Colorado.

MICROMET INC (MITI)

Micromet, Inc., a biopharmaceutical company, develops antibody-based products for cancer, inflammatory, and autoimmune diseases. Its products under clinical trials include MT103, a Phase I clinical trial product candidate for the treatment of patients with non-Hodgkins lymphoma; and Adecatumumab, a recombinant human monoclonal antibody that is under clinical Phase IIa status for metastatic breast cancer and other adenocarcinoma indications, and is being evaluated in clinical Phase Ib trials for treatment of metastatic breast cancer in combination with docetaxel. The company's preclinical development products include MT203 and MT204 human antibodies to treat various acute and chronic inflammatory diseases, including rheumatoid arthritis, asthma, psoriasis, and multiple sclerosis; EphA2, a cell surface membrane-associated receptor tyrosine kinase for the treatment of cancer; CEA, which is indicated for the treatment of tumors of epithelial origin, such as colorectal carcinoma, lung adenocarcinoma, mucinous ovarian carcinoma, and endometrial adenocarcinoma; MORAb28, a human IgM monoclonal antibody binding to an antigen that is identified as a cell-surface antigen present on human melanomas and tumors of neuroectodermal origin; and MT110, a molecule that combines binding specificities for EpCAM and for CD3 on T cells. Micromet's product pipeline also consists of D93, a humanized, anti-metastatic, and anti-angiogenic monoclonal antibody for treatment of patients with solid tumors. It has strategic collaborations with MedImmune, Inc. for MT103; Nycomed for development of anti-GM-CSF antibodies; and Merck Serono Biopharmaceuticals S.A. for adecatumumab. The company is headquartered in Bethesda, Maryland.

ENZON PHARMACEUTICALS INC (ENZN)

Enzon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, manufacture, and commercialization of human therapeutics for life threatening diseases. The company markets four human therapeutic products, such as ABELCET, ONCASPAR, ADAGEN, and DEPOCYT. ABELCET is a lipid complex formulation of amphotericin B used primarily in the hospital to treat immuno-compromised patients with invasive fungal infections. ONCASPAR is a PEG-enhanced version of a naturally occurring enzyme called L-asparaginase. It is approved in the United States, Canada, and Germany; and is used in conjunction with other chemotherapeutics to treat patients with acute lymphoblastic leukemia who are hypersensitive or allergic to native or unmodified forms of L-asparaginase. ADAGEN is used to treat patients afflicted with a type of severe combined immunodeficiency disease, also known as the ‘Bubble Boy' disease, which is caused by the chronic deficiency of the adenosine deaminase enzyme. DEPOCYT is an injectable chemotherapeutic approved for the treatment of patients with lymphomatous meningitis. The company also develops PEG-INTRON, which is used in combination with REBETOL for the treatment of chronic hepatitis C; and ATG FRESENIUS S, a polyclonal antibody preparation that is used for T-lymphocyte suppression in organ transplant patients in order to prevent organ graft rejection. The company has strategic alliances with Nektar Therapeutics, SkyePharma, PLC, and Inex Pharmaceuticals Corporation. Enzon Pharmaceuticals was incorporated in 1981 and is headquartered in Bridgewater, New Jersey.

EXELIXIS INC (EXEL)

Exelixis, Inc. engages in the discovery and development of pharmaceutical products for the treatment of cancer, metabolic disorders, cardiovascular disease, and other serious diseases. Its clinical development pipeline includes various compounds in cancer and renal disease: XL119 (becatecarin), which is in a Phase III clinical trial in patients with inoperable bile duct tumors and which was exclusively licensed to Helsinn Healthcare SA with rights to reacquire commercial rights for North America; XL647, XL999, XL880, and XL820 that are in Phase I clinical trials in cancer; and XL844 and XL184, anticancer compounds for which it filed investigational new drug applications. The company's preclinical pipeline comprises six programs. The preclinical oncology programs consist of development candidates that focus on inhibiting the RAF (XL281), Akt/S6k (XL418), and IGF1R (XL228) kinases that are implicated in various cancers. In preclinical metabolic disease programs, which consist of Liver X Receptor, Farnesoid X Receptor, and Mineralocortiocoid Receptor programs, the company is developing small molecules that modulate nuclear hormone receptors implicated in various metabolic and cardiovascular disorders. Exelixis has alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, and Genentech. The company was founded as Exelixis Pharmaceuticals, Inc. in 1994 and changed its name to Exelixis, Inc. in 2000. Exelixis is headquartered in South San Francisco, California.

DENDREON CORPORATION (DNDN)

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of targeted therapies for cancer. Its portfolio of product candidates includes therapeutic vaccines, monoclonal antibodies, and small molecules to treat a range of cancers. The company's lead product candidate, Provenge (sipuleucel-T), is an investigational active cellular immunotherapy in Phase III clinical trials for the treatment of metastatic, androgen independent prostate cancer. In addition, Dendreon completed Phase I clinical trials for Neuvenge (lapuleucel-T), an investigational active cellular immunotherapy for the treatment of breast, ovarian, and other solid tumors. Its preclinical programs include monoclonal antibodies, therapies targeting the trp-p8 pathway and serine protease product candidates for the treatment of cancer. The company has research and development alliances with Genentech, Inc.; Abgenix, Inc.; and Dyax Corp. Dendreon was formed in 1992 and is headquartered in Seattle, Washington.

NABI BIOPHARMACEUTICALS (NABI)

Nabi Biopharmaceuticals engages in the development and commercialization of products in the areas of Gram-positive bacterial infections, hepatitis, nephrology, and nicotine addiction. The company markets three products: PhosLo for treatment of hyperphosphatemia in end-stage renal failure patients; Nabi-HB for the prevention of hepatitis B infections; and Aloprim for the treatment of chemotherapy-induced hyperuricemia or high uric acid levels. Nabi also has products in various stages of clinical and preclinical development. Its advanced StaphVAX, which is in Phase III clinical development, is designed to prevent the most dangerous and prevalent strains of Staphylococcus aureus bacterial infections. The company's other products in development include Altastaph, an antibody for prevention of Staphylococcus aureus infections; NicVAX, a vaccine to treat nicotine addiction; and Civacir, an antibody for preventing hepatitis C virus reinfection in liver transplant patients. The company also offers contract manufacturing services. Nabi sells its biopharmaceutical products to wholesalers, distributors, hospitals, and home healthcare companies, as well as sells its antibody products to pharmaceutical and diagnostic product manufacturers. The company has strategic alliances with Public Health Services/National Institutes of Health; Chiron Corporation; Pfizer; and Cambrex BioScience of Baltimore, Inc. Nabi is headquartered in Boca Raton, Florida.

THRESHOLD PHARMACEUTICALS INC (THLD)

Threshold Pharmaceuticals, Inc., a development stage company, engages in the discovery, development, and commercialization of small molecule therapeutics based on ‘Metabolic Targeting'. Metabolic Targeting is an approach that targets fundamental differences in metabolism between normal and diseased cells. The company focuses on the treatment of cancer and benign prostatic hyperplasia (BPH), a disease characterized by overgrowth of the prostate. Its three product candidates include glufosfamide, which in the Phase 3 clinical trial for the second-line treatment of pancreatic cancer; TH-070, another product candidate for the treatment of BPH, which is in Phase 2 clinical trial; and 2-Deoxyglucose, for the treatment of solid tumors. The company was founded by George F. Tidmarsh. Threshold Pharmaceuticals was incorporated in 2001 and is headquartered in Redwood City, California.

KERYX BIOPHARMACEUTICALS INC (KERX)

Keryx Biopharmaceuticals, Inc., a development stage company, engages in the acquisition, development, and commercialization of pharmaceutical products for the treatment of diabetes and cancer. The company has two product candidates in the later stages of clinical development, which include sulodexide, or KRX-101, for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes; and perifosine or KRX-0401 for the treatment of multiple forms of cancer. Its other drug portfolio includes three clinical stage oncology compounds, designated as KRX-0402 and KRX-0403. The company has strategic alliances with Alfa Wassermann S.p.A.; Zentaris AG; Opocrin, S.p.A.; Paligent, Inc.; Collaborative Study Group; and Prescient NeuroPharma, Inc. The company was incorporated in 1998 under the name Paramount Pharmaceuticals, Inc. and changed its name to Lakaro Biopharmaceuticals, Inc. in 1999 and to Keryx Biopharmaceuticals, Inc. in 2000. Keryx Biopharmaceuticals is headquartered in New York City.

MAXYGEN INC (MAXY)

Maxygen, Inc., a biotechnology company, focuses on using protein optimization and modification technologies to create and develop products for human therapeutics applications. It engages in the development of novel products for the treatment and prevention of a range of diseases, such as cancer, multiple sclerosis, HIV, and hepatitis. The company's product pipeline comprises MAXY-ALPHA, an optimized interferon alpha to treat hepatitis C; MAXY-GCSF, an improved colony stimulating factor (G-CSF) to treat neutropenia; MAXY-FACTOR VII, an improved factor VII for uncontrolled bleeding indications; and MAXY-GAMMA, an optimized interferon gamma to treat idiopathic pulmonary fibrosis and other severe diseases. Maxygen also has interest in Codexis, Inc., which provides biocatalysis and fermentation processes and products to the life science and fine chemical industries. The company has strategic alliances with F. Hoffmann-La Roche, Ltd. and InterMune, Inc. Maxygen was co-founded by Russell J. Howard and Isaac Stein. The company was incorporated in 1996 and is headquartered in Redwood City, California.

CORNERSTONE THERAPEUTICS INC (CRTX)

Critical Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of products to treat respiratory, inflammatory, and critical care diseases. The company's primary product is Zyflo Filmtab, a tablet formulation of zileuton for the prevention and chronic treatment of asthma. Its products under development include Zileuton, through development of additional formulations, controlled-release formulation and an intravenous formulation; CTI-01, a small molecule product candidate for patients who are at high risk for post-surgical complications following cardiopulmonary bypass; HMGB1, a cytokine, for the development of products to treat inflammation-mediated diseases; and Alpha-7, a small molecules designed to inhibit the body's inflammatory response by acting on the nicotinic alpha-7 cholinergic target. Critical Therapeutics has strategic collaboration with MedImmune, Inc. and Beckman Coulter, Inc. The company was co-founded by Mitchell Fink, Kevin Tracey, and H. Shaw Warren. Critical Therapeutics was incorporated in 2000 as Medicept, Inc. and changed its name to Critical Therapeutics, Inc. in 2001. The company is headquartered in Lexington, Massachusetts.

ANIKA THERAPEUTICS INC (ANIK)

Anika Therapeutics, Inc. engages in the development, manufacture, and commercialization of therapeutic products and devices that are designed to repair, protect and heal bone, cartilage, and soft tissue. Its products are based on hyaluronic acid (HA), a naturally occurring, biocompatible polymer found throughout the body. HA enhances joint function and coats, protects, cushions, and lubricates soft tissues. The company's products include ORTHOVISC and HYVISC, an HA product used in the treatment of joint diseases, such as osteoarthritis, and viscoelastic products used in eye surgery. The ophthalmic products include AMVISC and AMVISC Plus product line, CoEase, STAARVISC-II, and ShellGel. Its injectable ophthalmic viscoelastic products are molecular weight HA products used as viscoelastic agents in ophthalmic surgical procedures, such as cataract extraction and intraocular lens implantation. The company operates in the United States and Canada, the United Kingdom, Italy, and other European countries, Turkey, and parts of the Middle East. Anika Therapeutics was founded in 1983 and is headquartered in Woburn, Massachusetts.

MYRIAD GENETICS INC (MYGN)

Myriad Genetics, Inc., a biopharmaceutical company, engages in the development and marketing of therapeutic and molecular diagnostic products. Its lead drug candidate is Flurizan, a therapeutic drug for the treatment of Alzheimer's disease, which completed a Phase II human clinical trial in patients with mild to moderate Alzheimer's disease. Flurizan is also in a Phase IIb human clinical trial for the treatment of patients with premetastatic prostate cancer. The company's other products under development include MPC-6827, a small-molecule drug candidate that inhibits tubulin, an important protein involved in cell division for treatment of advanced solid tumors or metastatic brain tumors; MPC-2130, a novel apoptosis inducing small molecule for the treatment of metastatic tumors or blood cancers, as well as refractory cancer, ovarian cancer, and prostate cancer; and MPI-49839, a viral budding inhibitor for the treatment of AIDS. It also offers various predictive medicine products, including BRACAnalysis, which assesses a woman's risk of developing breast and ovarian cancer; COLARIS and COLARIS AP, which determine a person's risk of developing colon cancer; and MELARIS, which assesses a person's risk of developing malignant melanoma. Myriad Genetics has strategic alliances with Abbott Laboratories and E.I. du Pont de Nemours and Company. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.

ENZO BIOCHEM INC (ENZ)

Enzo Biochem, Inc., together with its subsidiaries, engages in the research, development, manufacture, and marketing of diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects, and other medically pertinent diagnostic information. The company's major product categories include preformatted in situ kits, preformatted microplate kits, membrane kits, labeled probes, and labeling and signaling reagents. It is also conducting research and development activities in the development of therapeutic products based on the company's technology platform of genetic modulation and immune modulation. Enzo Biochem is evaluating its proprietary gene medicine for HIV-1 infection, as well as its proprietary immune regulation medicines for hepatitis B and hepatitis C infection, and for Crohn's Disease. In addition, it operates a regional clinical reference laboratory that provides diagnostic services to the greater New York and New Jersey medical community. This laboratory offers a menu of routine and esoteric clinical laboratory tests or procedures. These tests are frequently used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. Enzo Biochem markets its products and services through direct sales, manufacturers, and distributors. The company was co-founded by Elazar Rabbani, Shahram K. Rabbani, and Barry W. Weiner in 1976. Enzo Biochem is headquartered in Farmingdale, New York.

BIODELIVERY SCIENCES INTERNATIONAL INC (BDSI)

BioDelivery Sciences International, Inc. operates as a specialty biopharmaceutical company that uses its licensed and patented drug delivery technologies to develop and commercialize new formulations of proven therapeutics targeted at acute treatment opportunities, such as pain, anxiety, nausea and vomiting, and infections. Its lead product under development is Emezine, which is used for treating nausea and vomiting, is in pre-registration stage. The company's licensed drug delivery technologies include the Bioral nanocochleate drug delivery technology, which is designed for a range of applications; and the BEMA drug delivery disc technology, which is applied to the inner cheek membrane. Its Bioral Amphotericin B is an anti-fungal treatment for treating systemic fungal infections. The company's lead BEMA product under development is BEMA Fentanyl, a treatment for cancer pain. BioDelivery Sciences is also developing BEMAT Long Acting Analgesic for treating pain conditions, including post operative and chronic pain due to osteoarthritis, lower back disorders, and rheumatoid arthritis. In addition, the company has a clinical development and license agreement with Clinical Development Capital, LLC relating to its BEMA Fentanyl product. BioDelivery Sciences was incorporated in 1997 and is headquartered in Morrisville, North Carolina.

OREXIGEN THERAPEUTICS INC (OREX)

Orexigen Therapeutics, Inc. operates as a biopharmaceutical company focusing on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. Its lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II development. These two product candidates are designed based on the company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss. The company was founded in 2002 and is headquartered in San Diego, California.

TRIMERIS INC (TRMS)

Trimeris, Inc. engages in the identification, development, and commercialization of therapeutic agents that block viral infection by inhibiting viral fusion with host cells. Its principal drug candidate, Fuzeon, is a human immunodeficiency virus (HIV) fusion inhibitor approved in the United States, Canada, European Union, and other countries for the treatment of HIV-1 infection in treatment-experienced patients with evidence of HIV-1 replication despite ongoing antiretroviral therapy. The company has a collaboration agreement with F. Hoffmann-La Roche, Ltd. to develop and market Fuzeon and T-1249, a replacement compound. Trimeris was founded by Dani Bolognesi and Tom Matthews in 1993 and is based in Morrisville, North Carolina.

CAMBREX CORPORATION (CBM)

Cambrex Corporation and its subsidiaries provide products and services to accelerate drug discovery, development, and manufacturing processes for human therapeutics worldwide. It operates through three segments: Bioproducts, Biopharma, and Human Health. The Bioproducts segment offers research products and therapeutic application products; The Biopharma segment provides contract biopharmaceutical process development and manufacturing services; and The Human Health segment produces active pharmaceutical ingredients and pharmaceutical intermediates for use in the production of prescription and over-the-counter drug products, as well as other custom chemicals derived from organic chemistry. Cambrex Corporation sells its products through its direct sales force, independent distributors, and its e-commerce Web site to pharmaceutical and biopharmaceutical companies, generic drug companies, biotechnology companies, and research organizations. The company was founded in 1981 and is based in East Rutherford, New Jersey.

BIOSANTE PHARMACEUTICALS INC (BPAX)

No description available.

ADEONA PHARMACEUTICALS INC (AEN)

Austral Pacific Energy, Ltd. engages in the acquisition, exploration, and development of oil and gas properties in New Zealand, Papua New Guinea, and Australia. It holds varying net interests equivalent to approximately 2.6 million acres of exploration permits in New Zealand and 0.8 million acres of exploration interests in Papua New Guinea. The company was incorporated as Pryme Energy Resources, Ltd. in 1979 and subsequently changed its name to Indo-Pacific Energy, Ltd. Its name was further changed to Austral Pacific Energy, Ltd. in 2003. The company is based in Wellington, New Zealand.

VERTEX PHARMACEUTICALS INCORPORATED (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in the discovery, development, and commercialization of small molecule drugs for HIV infection, chronic hepatitis C virus infection, inflammatory and autoimmune disorders, cancer, pain, and bacterial infection. It offers Lexiva/Telzir and Agenerase for HIV infection. The company is developing Merimepodib and VX-950, which are in phase I and phase II stage; VX-765, VX-702, and Pralnacasan that are in phase II stage; VX-680, VX-944, and VX-322, which are in phase I and preclinical stage; and VX-409 and VX-692, that are in preclinical stage. Vertex Pharmaceuticals has collaboration agreements with Aventis S.A.; GlaxoSmithKline plc; Novartis Pharma AG; Merck &amp; Co., Inc.; Mitsubishi Pharma Corp.; and Cystic Fibrosis Foundation Therapeutics Incorporated. It also has collaboration agreements with Schering AG; Kissei Pharmaceutical Co., Ltd.; and Eli Lilly and Company. In addition, it has a licensing agreement with Avalon Pharmaceuticals, Inc. for the development and commercialization of the IMPDH inhibitor VX-944 for the treatment of cancer. Vertex Pharmaceuticals was founded by Joshua Boger in 1989 and is headquartered in Cambridge, Massachusetts.

OPTIMER PHARMACEUTICALS INC (OPTR)

Optimer Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing anti-infective products primarily to treat gastrointestinal infections and related diseases. Its product candidates include Difimicin (OPT-80), which is in Phase 3 registration trial for the treatment of Clostridium Difficile-associated diarrhea (CDAD), and for the prevention of CDAD; and prevention of nosocomial vancomycin-resistant enterococci bloodstream infections, and methicillin-resistant staphylococci prophylaxis. The company is also developing Prulifloxacin, which is under Phase 3 trial for the treatment of infectious diarrhea, including traveler's diarrhea; OPT-88, a therapy for osteoarthritis; OPT-822/OPT-821, a cancer immunotherapy for the treatment of metastatic breast cancer; and OPT-1068 and OPT-1273 antibiotics for the treatment of upper and lower respiratory tract infections. It has a collaboration agreement with Par Pharmaceutical, Inc. for the clinical development and commercialization of Difimicin; as well as a collaborative research and development, and license agreement with Cempra Pharmaceuticals, Inc. to discover, develop, and commercialize drugs based on macrolide and ketolide compounds. Optimer Pharmaceuticals was founded in 1998 and is headquartered in San Diego, California.

ADOLOR CORPORATION (ADLR)

Adolor Corporation, a development stage biopharmaceutical corporation, engages in the discovery, development, and commercialization of prescription pain management products primarily in the United States. Its lead product candidate, Entereg, is a small molecule, peripherally-acting mu opioid receptor antagonist. As of July 6, 2005, the company was under development of Entereg for the management of the gastrointestinal side effects associated with opioid use. Adolor other products under development include a sterile lidocaine patch, is in Phase 2 clinical development, for treating postoperative incisional pain, and analgesics for treating moderate-to-severe pain conditions. The company has collaboration agreement with Glaxo Group Limited for the development and commercialization of Entereg in multiple indications. It also has a license agreement with EpiCept Corporation to develop and commercialize a sterile lidocaine patch in North America. Adolor was formed in 1993 and is headquartered in Exton, Pennsylvania.

XENOPORT INC (XNPT)

XenoPort, Inc. develops and markets applications to enhance bioavailability of drugs. The company's product Transported Prodrug uses transporter genomics, assay technology, and proprietary chemistries to introduce therapeutic molecules into cells. Additionally, it provides solution to improve expiring drugs. XenoPort was founded in 1999 and is headquartered in Santa Clara, California.

NOVAVAX INC (NVAX)

Novavax, Inc. engages in the research, development, and commercialization of products for women's health and infectious diseases. Its primary product candidate ESTRASORB, a topical emulsion for estrogen therapy, is used for the treatment of vasomotor symptoms associated with menopause. The company's other products comprise a line of prenatal multivitamin tablets, including Novanatal, NovaStart, and Nestabs for use before, during, and after pregnancy; Gynodiol, an oral estrogen replacement therapy; AVC Cream for the treatment of vaginal infection; and Analpram HC for relief of inflammation and pruritus associated with conditions, such as hemorrhoids and anal fissures. Novavax is also developing ANDROSORB, a topical lotion for testosterone replacement therapy in women; ANDRO-Ject, which delivers therapeutic levels of androgen using a subcutaneous testosterone delivery system; and delivery systems, and therapeutic and preventative vaccines for various markets. In addition, the company conducts research and development on preventative vaccines and proteins for infectious diseases and cancers; and tolerogens to prevent the initiation and progression of stroke, heart attack, and other inflammatory diseases. Novavax has collaborative agreements with the National Institutes of Health for the development of AIDS vaccine and an avian flu vaccine to prevent a pandemic outbreak; National Cancer Institute to develop anticancer vaccines for the treatment of melanoma; NIAID, Walter Reed Army Institute for Research, and GlaxoSmithKline Pharmaceuticals for the development of vaccines to prevent hepatitis caused by Hepatitis E virus; and with Wave Biotech LLC to develop pandemic influenza vaccine production technologies. The company sells its products to obstetricians, gynecologists, managed care organizations, wholesalers, and retail pharmacies through direct sales force and distributors in the United States. Novavax was formed in 1987 and is headquartered in Malvern, Pennsylvania.

AMGEN INC (AMGN)

Amgen, Inc., a biotechnology company, engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. The company markets human therapeutic products in the areas of nephrology, supportive cancer care, and inflammatory disease. Its products primarily include EPOGEN, Aranesp, Neulasta, NEUPOGEN, and ENBREL, which is marketed under a co-promotion agreement with Wyeth in the United States and Canada. EPOGEN and Aranesp stimulate the production of red blood cells to treat anemia. Neulasta and NEUPOGEN selectively stimulate the production of neutrophils, a type of white blood cell that helps the body fight infections. ENBREL blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. It sells its products to healthcare providers, including clinics, hospitals, and pharmacies primarily in the United States, Europe, Canada, and Australia. Amgen has collaboration and license agreement with Memory Pharmaceuticals Corp. to produce drugs for neurological and psychiatric disorders; and a drug-discovery agreement with Galapagos Genomics NV. The company was established by Bill Bowes, Franklin Johnson, Sam Wohlsteadter, and Raymond Baddour in 1980. Amgen is headquartered in Thousand Oaks, California.

CELGENE CORPORATION (CELG)

Celgene Corporation engages in the discovery, development, and commercialization of therapies designed to treat cancer and immunological diseases through regulation of cellular, genomic, and proteomic targets. Its lead product, THALOMID, is used for the treatment of acute cutaneous manifestations of moderate to severe erythema nodosum leprosum, and as maintenance therapy to prevent and suppress cutaneous manifestation recurrences. The company, through a supply and distribution agreement, with GlaxoSmithKline, distributes ALKERAN, a therapy for the palliative treatment of multiple myeloma and for palliation of carcinoma of the ovary. Its RITALIN family of drugs includes Focalin (d-MPH), which is used for the treatment of attention deficit disorder and attention deficit hyperactivity disorder in school-age children. The company has various products in the preclinical and clinical-stage, including immunomodulatory drugs and selective cytokine inhibitory drugs. Celgene also produces compounds such as Benzopyrans and Selective Estrogen Receptor Modulators, Kinases Inhibitors, Tubulin Inhibitors, and Ligase Modulators. The company has collaborative agreements with Novartis Pharma AG; and strategic partnership agreements with Pharmion Corporation, Penn Pharmaceuticals Services Limited, and GlaxoSmithKline. The company markets and sells its products in the United States and Canada primarily through wholesale distributors. Celgene was organized in 1980 as a unit of Celanese Corporation and was spun-off in 1986. The company is headquartered in Warren, New Jersey.

OSIRIS THERAPEUTICS INC (OSIR)

Osiris Therapeutics, Inc., a biotechnology company, commercializes stem cell products from adult bone marrow in the United States. It develops and markets products to treat medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The company's products include Osteocel for use in spinal fusion and other orthopedic surgical procedure; and Prochymal, a phase II and III clinical trial product for the treatment of steroid refractory Graft versus Host Disease (GvHD), acute GvHD, and Crohn's Disease. It also offers Chondrogen, which is in phase I/II clinical trial used for the treatment of meniscus regeneration and cartilage protection; and Provacel, a phase I clinical trial product for repairing heart tissue following a heart attack. Osiris Therapeutics has strategic alliance with JCR Pharmaceuticals Co., Ltd.; and collaboration agreement with Boston Scientific Corporation to develop applications of MSC technology to treat acute myocardial infarction and chronic ischemia. The company was founded in 1992 and is headquartered in Baltimore, Maryland.

AFFYMETRIX INC (AFFX)

Affymetrix, Inc. engages in the development, manufacture, sale, and service of systems for genetic analysis for use in the life sciences and in clinical diagnostics. The company's GeneChip system consists of components, including disposable probe arrays containing genetic information on a chip, reagents for extracting, amplifying, and labeling target nucleic acids, a fluidics station for introducing the test sample to the probe arrays, a hybridization oven for optimizing the binding of samples to the probe arrays, a scanner to read the fluorescent image from the probe arrays, and software to analyze and manage the resulting genetic information. The company also offers related microarray technology, which includes instrumentation, software, and licenses for fabricating, scanning, collecting, and analyzing results from low density microarrays. It sells its products to pharmaceutical, biotechnology, agrichemical, diagnostics, and consumer products companies, as well as academic research centers, government research laboratories, private foundation laboratories, and clinical reference laboratories in North America and Europe. Affymetrix has an agreement with The Jeffrey Modell Foundation and National Human Genome Research Institute to develop two molecular DNA tests that could help save the lives of children born with severe combined immunodeficiency and other primary immunodeficiency disorders; a collaboration with CureSearch Children's Oncology Group to discover and validate gene expression signatures, or genetic fingerprints, for various common childhood cancers, including leukemia and sarcoma, a common solid tumor; and a collaboration with Imperial College London and the Medical Research Council to discover the genetic variations associated with cancer, cardiovascular disease, and diabetes. The company was founded in 1991 and is headquartered in Santa Clara, California.

ALIMERA SCIENCES INC (ALIM)

Alimera Sciences, Inc., a biopharmaceutical company, focuses on the research, development, and commercialization of ophthalmic pharmaceuticals. It develops pharmaceuticals for diseases affecting the back of the eye or retina. The companyÂ's product candidates include Iluvien, an intravitreal insert that provides a sustained therapeutic effect for up to 36 months in the treatment of diabetic macular edema; or DME, a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness, as well as other ophthalmic diseases, such as the wet form of age-related macular degeneration (AMD), the dry form of AMD, and retinal vein occlusion. It also conducts testing on two classes of Nicotinamide Adenine Dinucleotide Phosphate oxidase inhibitors. The company was founded in 2003 and is headquartered in Alpharetta, Georgia.

VANDA PHARMACEUTICALS INC (VNDA)

Vanda Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on the development and commercialization of clinical-stage drug candidates for various central nervous system disorders. It offers iloperidone, a compound for the treatment of schizophrenia and bipolar disorder; and VEC-162, a compound for the treatment of sleep and mood disorders. The company also provides VSF-173, a compound for the treatment of excessive sleepiness. Vanda Pharmaceuticals was founded in 2002 and is headquartered in Rockville, Maryland.

ISIS PHARMACEUTICALS INC (ISIS)

Isis Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of drugs to treat various therapeutic areas, including inflammatory, metabolic, and cardiovascular diseases, as well as cancer. The company operates through two segments, Drug Discovery and Development, and Ibis. The Drug Discovery and Development segment develops antisense inhibitors through its proprietary technology. The company markets its antisense drug, Vitravene, for the treatment of cytomegalovirus and retinitis in AIDS patients in the United States and Europe. It also develops new formulations of antisense drugs, such as oral, topical cream, subcutaneous, intravitreal, aerosol, and enema. The company's drugs under development include Alicaforsen for Ulcerative Colitis in Phase II clinical trial and ISIS 113715 for diabetes in Phase II clinical trial. In addition, it develops second-generation inhibitors, such as apoB-100 for the lowering of cholesterol and ISIS 301012, a Phase I study of an oral capsule formulation. The Ibis segment offers Triangulation Identification for Genetic Evaluation of Risks (TIGER) technology, a biosensor system, for identification of infectious diseases. TIGER biosensor system identifies various bacteria and viruses in both environmental and human clinical samples and used for epidemiological surveillance, biological products screening, and microbial forensics applications. The company has strategic alliance and collaboration agreements with Novartis Ophthalmics AG; Ercole Biotech, Inc.; Alnylam Pharmaceuticals, Inc.; OncoGenex Technologies, Inc.; Santaris Pharma A/S; Eli Lilly and Company; Antisense Therapeutics, Ltd.; and Sarissa, Inc. Isis Pharmaceuticals was founded in 1989 and is headquartered in Carlsbad, California.

LEXICON PHARMACEUTICALS INC (LXRX)

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of pharmaceutical products for the treatment of human disease. The company's drug candidates include LX6171, a Phase Ib clinical trial product for the treatment of cognitive impairment associated with disorders, such as Alzheimer's disease, schizophrenia, and vascular dementia; LX1031, a Phase Ia clinical trial product for the treatment of irritable bowel syndrome and other gastrointestinal disorders; LX2931, a preclinical development stage product for the treatment of autoimmune diseases, such as rheumatoid arthritis; and LX1032, a preclinical development stage product for the treatment of gastrointestinal disorders. It has also validated targets in drug discovery programs in various therapeutic areas, including diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders, and ophthalmic disease. The company has drug discovery alliances with Bristol-Myers Squibb Company to discover, develop, and commercialize new small molecule drugs in the neuroscience field; Genentech, Inc. to discover novel therapeutic proteins and antibody targets; N.V. Organon to discover, develop, and commercialize new biotherapeutic drugs; and Takeda Pharmaceutical Company Limited for the discovery of new drugs for the treatment of high blood pressure. Lexicon Pharmaceuticals, formerly known as Lexicon Genetics Incorporated, was founded in 1995 and changed its name to Lexicon Pharmaceuticals, Inc. in April 2007. The company is headquartered in The Woodlands, Texas.

PDL BIOPHARMA INC (PDLI)

PDL BioPharma, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of therapies for treatment of inflammation and autoimmune diseases, acute cardiac conditions, and cancer. It markets and distributes various biopharmaceutical products, including Cardene I.V. for the short-term treatment of hypertension; Retavase, a fibrinolytic agent for the management of acute myocardial infarction or heart attack in adults for the improvement of ventricular function; and IV Busulfex that is used as a conditioning agent in blood or marrow transplantation in chronic myelogenous leukemia. The company also develops various other products, such as Daclizumab for the treatment of asthma and multiple Sclerosis; Ularitide to treat decompensated congestive heart failure; Terlipressin for the treatment of Type 1 hepatorenal syndrome; HuZAF to treat crohn's disease; Nuvion for the treatment of severe steroid-refractory ulcerative colitis; and M200 to treat solid tumors. PDL BioPharma markets its biopharmaceutical products in the United States and Canada through its hospital sales force. The company was founded by Laurence Jay Korn in 1986. It was formerly known as Protein Design Labs, Inc. and changed its name to PDL BioPharma, Inc. in June 2005. PDL BioPharma is headquartered in Fremont, California.

HUMAN GENOME SCIENCES INC (HGSI)

Human Genome Sciences, Inc. operates as a biopharmaceutical company with a pipeline of novel protein and antibody drugs. The company's drugs in clinical development include LymphoStat-BTM for the treatment of lupus and rheumatoid arthritis; AlbuferonTM for the treatment of chronic hepatitis C; HGS-ETR1, HGS-ETR2, HGS-TR2J for the treatment of solid and hematopoietic cancers; CCR5 mAb for the treatment of HIV/ AIDS; and ABthraxTM for the treatment of anthrax infection. It has various strategic partners, including GlaxoSmithKline, Takeda, Schering-Plough, Sanofi-Synthelabo, Merck KGaA, Transgene, MedImmune, Inc., and Pharmacia &amp; Upjohn. Human Genome Sciences was founded in 1992 and is headquartered in Rockville, Maryland.

NEURALSTEM INC (CUR)

Neuralstem, Inc., a biotechnology company, engages in developing and commercializing treatments based on transplanting human neural stem cells. The company uses its proprietary human neural stem cell technology to create biotherapeutic products for the treatment of central nervous system diseases and various neurodegenerative conditions, and for the regenerative repair of acute diseases. Its proprietary technology is also used in small-molecule drug discovery. The company was founded in 1996 and is headquartered in Rockville, Maryland.

PEREGRINE PHARMACEUTICALS INC (PPHM)

Peregrine Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research, development, manufacture, and commercialization of biotherapeutics for the treatment of cancer, viruses, and other diseases using targeted antibodies. The company's products portfolio includes Cotara for brain cancer, which is in Phase II/III registration trial, and Tarvacin, an anti-phospholipid therapy agent for the treatment of solid tumors and chronic hepatitis C virus infection. Its vascular research programs fall under various technology platforms, including tumor necrosis therapy, antiphospholipid therapy, vascular targeting agents, antiangiogenesis, and vasopermeation enhancement agent technology. In addition, the company, through its wholly owned subsidiary, Avid Bioservices, Inc., provides a range of contract manufacturing services, including contract manufacturing of antibodies and proteins, cell culture development, process development, and testing of biologics for biopharmaceutical and biotechnology companies. The company was founded in 1981 as Techniclone International Corporation. It changed its name to Techniclone Corporation in 1997 and to Peregrine Pharmaceuticals, Inc. in 2000. Peregrine Pharmaceuticals is based in Tustin, California.

MYREXIS INC (MYRX)

Myriad Pharmaceuticals, Inc., a biopharmaceutical company, engages in the research and development of therapeutic drug candidates. The companyÂ's activities include identification of drug targets, discovery of molecules, development of drug candidates, and design and execution of clinical programs. It develops four drug candidates that involve in human clinical trials, as well as engages in the research and development of cancer and infectious disease drugs. The company was founded in 1998 and is based in Salt Lake City, Utah. Myriad Pharmaceuticals, Inc. (NasdaqGM:MYRX) operates independently of Myriad Genetics Inc. as of June 30, 2009.

ACORDA THERAPEUTICS INC (ACOR)

Acorda Therapeutics, Inc., a biopharmaceutical company, engages in the identification, development, and commercialization of various therapies for the improvement of neurological functions in people with multiple sclerosis (MS), spinal cord injury, and other disorders of the central nervous system in the United States. It markets Zanaflex Capsules and Zanaflex tablets, a short-acting drug indicated for the management of spasticity. The company's lead product candidate is Fampridine-SR, which is in a Phase III clinical trial for the improvement of walking ability in people with multiple sclerosis. Its preclinical programs comprise remyelination programs that include two distinct therapeutic approaches to stimulate repair of the damaged myelin sheath in MS, Glial Growth Factor 2, or GGF-2, and remyelinating antibodies; and Chondroitinase Program that develops second generation approaches to overcoming the proteoglycan matrix. Acorda Therapeutics sells its products through internal specialty sales force and contract pharmaceutical telesales organizations. The company was founded in 1995 and is based in Hawthorne, New York.

IMMUNOMEDICS INC (IMMU)

Immunomedics, Inc. engages in the development, manufacture, and commercialization of diagnostic imaging and therapeutic products for the detection and treatment of cancer, autoimmune, and other diseases. The company offers its CEA-Scan, a diagnostic imaging agent used for the detection of colorectal cancers, in the United States and Canada, as well as in Europe. It offers its LeukoScan, a diagnostic product used for the detection of bone infections, in Europe and Australia. Immunomedics' therapeutic product candidates primarily comprised epratuzumab, which completed certain Phase II clinical trials for the treatment of nonHodgkin's lymphoma, as well as labetuzumab, which was in Phase I/II clinical trials for the treatment of certain solid tumors and hematologic malignancies, as of June 30, 2004. The company was founded by David M. Goldenberg. Immunomedics was incorporated in 1982 and is headquartered in Morris Plains, New Jersey.

ENTREMED INC (ENMD)

EntreMed, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics primarily for the treatment of cancer. It develops multimechanism oncology and anti-inflammatory drugs that target disease cells directly and the blood vessels that nourish them. The company's lead drug candidate Panzem (2-methoxyestradiol or 2ME2) is in clinical trials for cancer, as well as in preclinical development for nononcology indications. Panzem is in Phase I and Phase II clinical trials. The company also develops various molecules, including analogs of 2ME2, modulators of fibroblast growth factor-2 activity, tissue factor pathway inhibitor peptides, and proteinase activated receptor-2 antagonists to inhibit tumor growth and angiogenesis activities. The company has a strategic alliance with Allergan to develop and commercialize small molecule angiogenic inhibitors for the treatment and prevention of diseases and conditions of the eye; research collaboration with Affymax, Inc. to identify lead tissue factor pathway inhibitor drug candidates for the treatment of cancer; and a cooperative research and development agreement with the National Cancer Institute to evaluate the role of HIF-1alpha inhibition in the treatment of cancer. EntreMed was incorporated in 1991 and is based in Rockville, Maryland.

PRANA BIOTECHNOLOGY LTD - AMERICAN DEPOSITARY SHARES EACH REPRESENTING TEN ORDINARY SHARES (PRAN)

Prana Biotechnology Limited, a development stage company, engages in the research and development of therapeutic drugs, which are designed to treat the underlying causes of degeneration of the brain and the eye as the aging process progresses. The company primarily focuses on Alzheimer's disease, age-related cataracts, Creutzfeldt-Jakob disease, Motor Neuron disease, and Parkinson's disease. Its development stage products include PBT-1 and PBT-2, which will be used for the treatment of Alzheimer disease. The company was co-founded by Geoffrey Paul Kempler. Prana Biotechnology was incorporated in 1997 and is based in Parkville, Australia.

GILEAD SCIENCES INC (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for patients suffering from life-threatening diseases primarily in North America, Europe, and Australia. It focuses its research and clinical programs on anti-infectives. The company's products include Viread, Emtriva, and Truvada, which are used for the treatment of human immunodeficiency virus infection in adults; AmBisome, an antifungal agent to treat serious invasive fungal infections caused by various fungal species; Hepsera, which is used for the treatment of chronic hepatitis B infection; Vistide, used for the treatment of cytomegalovirus retinitis; and DaunoXome, a liposomal formulation of the anticancer agent daunorubicin, for the treatment of AIDS-related Kaposi's sarcoma. Its products also comprise Tamiflu, which is used for the prevention and treatment of influenza; and Macugen, for the treatment of neovascular age-related macular degeneration. Gilead sells its products primarily through wholesalers and distributors. The company has collaborative relationships with Bristol-Myers Squibb Company; Achillion Pharmaceuticals, Inc.; EyeTech Pharmaceuticals, Inc.; Fujisawa Healthcare, Inc.; GlaxoSmithKline; Japan Tobacco, Inc.; Pfizer, Inc.; F. Hoffmann-La Roche, Ltd.; and Sumitomo Pharmaceuticals Co., Ltd. Gilead was founded by Michael Riordan in 1987. The company is headquartered in Foster City, California.

VICAL INCORPORATED (VICL)

Vical Incorporated engages in the research and development of biopharmaceutical products for the prevention and treatment of serious or life-threatening diseases. The company focuses on the development of biopharmaceutical product candidates based on its patented deoxyribonucleic acid (DNA) delivery technologies. It develops various DNA-based vaccines and therapeutics for the prevention or treatment of infectious diseases, cancer, and cardiovascular diseases. Vical primarily develops its cancer immunotherapeutics, Allovectin-7 and IL-2/Electroporation, as well as a plasmid DNA vaccine for cytomegalovirus. Allovectin-7, which completed its Phase II clinical trials, is a plasmid/lipid complex containing the DNA sequences encoding HLA-B7 and ß2 microglobulin, which together form a Class I Major Histocompatibility Complex antigen. Allovectin-7 is being developed as a treatment for metastatic melanoma, a form of skin cancer. IL-2/Electroporation program that is in Phase 1 clinical testing is a gene-based, electroporation enhanced delivery of interleukin-2, or IL-2, a potent immunotherapeutic agent, as a treatment for solid tumors, with an initial indication in metastatic melanoma. Vical also develops an anthrax vaccine, which is in Phase 1 clinical testing. The company was incorporated in 1987 and is based in San Diego, California.

GERON CORPORATION (GERN)

Geron Corporation, a biopharmaceutical company, engages in the development and commercialization of therapeutic and diagnostic products for cancer based on its telomerase technology, and cell-based therapeutics using its human embryonic stem cell (HESC) technology. The company develops anticancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and, through its licensees, telomerase-based oncolytic (cancer-killing) viruses. It uses HESCs for the manufacture of replacement cells and tissues. It intends to use HESC technology to enable the development of transplantation therapies, facilitate pharmaceutical research and development practices, and for research in human developmental biology. Geron Corporation's nuclear transfer technology is a method for generating whole animals from genetic material derived solely from the nucleus of a single cell obtained from an individual animal. The company was incorporated in 1990 and is headquartered in Menlo Park, California.

SAVIENT PHARMACEUTICALS INC (SVNT)

Savient Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products that target unmet medical needs. It sells and distributes a generic version of oxandrolone, which is used to promote weight gain following involuntary weight loss related to disease or medical condition. The company also sells and distributes the branded version of oxandrolone in the United States, under the name Oxandrin. Further, Savient Pharmaceuticals is developing Puricase, which is in Phase III clinical studies for the control of elevated levels of uric acid in the blood or hyperuricemia. It distributes its products to drug wholesaler customers in the United States. The company was founded in 1980 as Bio-Technology General Corp. and changed its name to Savient Pharmaceuticals, Inc. in 2003. Savient Pharmaceuticals is headquartered in East Brunswick, New Jersey.

QIAGEN NV - COMMON SHARES (QGEN)

QIAGEN N.V., through its subsidiaries, provides enabling technologies and products for the separation, purification, and handling of nucleic acids and proteins. It offers a portfolio of consumable products for nucleic acid and protein separation, purification and handling, and nucleic acid amplification, as well as automated instrumentation, synthetic nucleic acid products, and related services. Its consumable products applications include plasmid deoxyribonucleic (DNA) acid purification; ribonucleic acid (RNA) stabilization and purification; genomic and viral nucleic acid purification; nucleic acid transfection; PCR amplification; reverse transcription; DNA cleanup after PCR and sequencing; DNA cloning and protein purification. Its BioRobot systems offer automation of nucleic acid preparation in low, medium, or high throughput scale, as well as reaction set-up and other laboratory tasks. The company also offers custom services, small interfering RNA synthesis, whole genome amplification services, DNA sequencing, and noncGMP and cGMP DNA production on a contract basis. The company sells its products to academic research markets, and pharmaceutical and biotechnology companies, as well as developing commercial markets, including applied testing markets, clinical research, nucleic acid-based molecular diagnostics, and genetic vaccination, and gene therapy. It operates in the United States, Germany, Japan, the United Kingdom, Switzerland, France, Italy, Australia, Norway, Austria, Canada, Sweden, and the Netherlands. QIAGEN has a strategic alliance with Eppendorf AG to co-develop and co-market complementary and optimized products. The company was co-founded in 1984 by Detlev H. Riesner and Metin Colpan. QIAGEN is headquartered in Venlo, The Netherlands.

CYTORI THERAPEUTICS INC (CYTX)

Cytori Therapeutics, Inc. engages in developing and commercializing stem and regenerative cell therapies for cardiovascular disease, reconstructive surgery and serious, chronic, and life threatening conditions. The company develops various products that are in clinical testing stages, which include Celution System, a device that removes stem and regenerative cells from a patient's adipose tissue, as well as used in breast reconstruction applications; Celution PRS System that could be used in plastic and reconstructive surgeries; and Celution CV System for the treatment of chronic myocardial ischemia and heart attacks. Cytori Therapeutics also develops a Celution System, which is under preclinical stage, for investigative applications in gastrointestinal disorders, which could address fistulas and wounds associated with inflammatory disorders, such as Crohn's disease and intestinal repair; peripheral vascular disease; and orthopedic applications, such as bone and spinal disc repair. In addition, it operates a tissue bank facility for the preservation of stem and regenerative cells extracted from adipose tissue. Further, Cytori Therapeutics manufactures macropore biosurgery products that include HYDROSORB family of spine and orthopedic implant products; and thin film bioresorbable soft tissue separation implant products. It has strategic joint venture with Olympus Corporation to develop and manufacture future generation devices based on its Celution system. The company was founded in 1996. It was formerly known as MacroPore, Inc. and changed its name to MacroPore Biosurgery, Inc. Further, the company changed its name to Cytori Therapeutics, Inc. in 2005. Cytori Therapeutics is headquartered in San Diego, California.

MOMENTA PHARMACEUTICALS INC (MNTA)

Momenta Pharmaceuticals, Inc. engages in structural analysis and design of complex sugars for the development of improved versions of existing drugs, the development of novel drugs, and the discovery of new biological processes. The company's products include M-Enoxaparin, a technology-enabled generic version of Lovenox and a low molecular weight heparin(LMWH), which is used to prevent and treat deep vein thrombosis and treat acute coronary syndromes; M-Dalteparin, also a technology-enabled generic version of the LMWH Fragmin. It also offers Glycoproteins, M118, pulmonary delivery of proteins, and sugar therapeutic, which are in preclinical stages. The company has collaboration agreements with Sandoz and Siegfried, Inc. and Siegfried, Ltd. The company was founded by Ganesh Venkataraman in 2001 as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in 2002. Momenta is based in Cambridge, Massachusetts.

ANTIGENICS INC (AGEN)

Antigenics, Inc., a biotechnology company, engages in the research and development of technology and products to treat cancers, infectious diseases, and autoimmune disorders. The company's principal product candidate, Oncophage, a personalized cancer vaccine, is in phase III clinical trials for the treatment of renal cell carcinoma and for metastatic melanoma, as well as in phase I/II trial for lung cancer. Its product portfolio also includes AG-858, a personalized cancer vaccine in a phase II clinical trial for the treatment of chronic myelogenous leukemia; AG-702/AG-707, a therapeutic vaccine program in phase I clinical development for the treatment of genital herpes; and Aroplatin, a liposomal chemotherapeutic for colorectal cancer and other solid tumors. The company was founded as Antigenics L.L.C. in 1994 and changed its name to Antigenics, Inc. in 2000. Antigenics is headquartered in New York City.

STEMCELLS INC (STEM)

StemCells, Inc., a biotechnology company, engages in the discovery, development, and commercialization of stem cell-based therapies to treat diseases of the nervous system, liver, and pancreas. It develops therapies that use stem and progenitor cells to treat human diseases and injuries, such as neurodegenerative diseases, including Batten's, Parkinson's, and Alzheimer's diseases, and other metabolic genetic disorders. The company also develops its products for demyelinating disorders, including spinal cord injuries, stroke, hepatitis, chronic liver failure, and diabetes; and multiple sclerosis. StemCells is headquartered in Palo Alto, California.

CELLDEX THERAPEUTICS INC (CLDX)

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of vaccines and targeted immunotherapeutics for the treatment of cancer, infectious, and inflammatory diseases. The company focuses on the use of tumor-specific targets and human monoclonal antibodies to precisely deliver therapeutic agents through targeted immunization approach. It also offers bacterial vector delivery technologies with manufacturing and preservation processes that offer the potential for a new generation of infectious disease vaccines. The company's products include Rotarix for the prevention of rotavirus infection; and two human food safety vaccines for reducing salmonella infection in chickens and eggs. Its product pipeline also consists of products in various stages of development, including CDX-110, which is undergoing evaluation in a Phase 2/3 clinical trial for the treatment of glioblastoma multiforme, an aggressive form of brain cancer; CDX-1307, a product based on its proprietary APC Targeting Technology, which is in two Phase 1 clinical trials for patients with advanced pancreatic, bladder, breast, and colon cancer; a TP10, a complement inhibitor for transplantation and other indications; and three candidates based on its oral, rapidly-protecting, single-dose, and temperature-stable vaccine technology, such as combination vaccines for travelers, the military, and health needs. AVANT Immunotherapeutics has collaborative agreements with GlaxoSmithKline for the development and commercialization of oral rotavirus vaccine; Pfizer, Inc. for discovery and development of vaccines to protect animals, and to develop CDX-110; and Select Vaccines Limited for the development of viral vaccines. The company, formerly known as AVANT Immunotherapeutics, Inc., was founded in 1983 and is headquartered in Needham, Massachusetts.

REXAHN PHARMACEUTICALS INC (RNN)

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of treatments for cancer, central nervous system (CNS) disorders, sexual dysfunction, and other unmet medical needs in the United States. Its products portfolio comprises Archexin, a Phase II clinical trials product for the treatment of renal cell carcinoma; Serdaxin, a Phase II clinical trials initiated product for the treatment of depression and mood disorders; and Zoraxel, a CNS-based sexual dysfunction drug, which is a Phase II clinical trials initiated product for the treatment of erectile dysfunction. The company's pre-clinical pipeline products include RX-0201-Nano, a nanoliposomal anti-cancer Akt-1 inhibitor; RX-0047-Nano, a nanoliposomal anti-cancer HIF-1 alpha inhibitor; and Nano-polymer anticancer drugs. Rexahn Pharmaceuticals has collaboration and license arrangements with UPM Pharmaceuticals, Inc.; Korean Research Institute of Bioscience and Biotechnology; Ewha Womans University; Amarex, LLC; Korea Research Institute of Chemical Technology; The University of Maryland; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Formatech, Inc. The company is based in Rockville, Maryland.

RTI BIOLOGICS INC (RTIX)

Regeneration Technologies, Inc. and its subsidiaries engage in the processing and sterilization of human tissue into allograft implants for orthopedic, oral maxillofacial, urinary, and cardiovascular surgeries. It processes human musculoskeletal and other tissues, including bone, cartilage, tendon, ligament, pericardial, and cardiovascular tissue in producing allograft implants. These tissues are used by surgeons to repair and promote the healing of various bone and other tissue defects, including spinal vertebrae repair, musculoskeletal reconstruction, fracture repair, repairs to the jaw and related tissues, and heart valve disorders. The company's processed Allografts include its patented MD Series Threaded Cortical Bone Dowels, Cornerstone Machined Allografts, Tangent Impacted Cortical Wedges, Opteform and Optefil allograft pastes, Osteofil/Regenafil injectable bone paste, and Precision Graft Cortical Rings. Regeneration Technologies provides its portfolio of products in a range of markets, including spinal, sports medicine, cardiovascular, and other general orthopedic applications. It distributes its products in the United States, Korea, and Europe. The company was incorporated in 1997 and is headquartered in Alachua, Florida.

GTX INC (GTXI)

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics primarily related to the treatment of serious men's health conditions and oncology. The company's drug discovery and development programs focus on small molecules that selectively modulate the effects of estrogens and androgens, two essential classes of hormones. It markets FARESTON, a toremifene citrate tablets, for the treatment of metastatic breast cancer. GTx develops ACAPODENE for two separate indications in men, a Phase III clinical trial product, for the prevention of prostate cancer in high risk men, and a Phase III clinical trial product for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer. The company also develops andarine, a selective androgen receptor modulator (SARM); as well as a second SARM, ostarine, for andropause and other chronic conditions related to aging, including sarcopenia. Further, its preclinical pipeline includes the specific product candidates prostarine, a SARM for benign prostatic hyperplasia, and andromustine, an anticancer drug, for hormone refractory prostate cancer. Additionally, it develops andarine for the treatment of cachexia from various types of cancer. The company has joint collaboration and license agreement with Ortho Biotech Products L.P. for the clinical development of andarine and specified backup SARM compounds. It also has collaboration agreements with Hybritech, Inc., diaDexus, Inc., and Tessera, Inc. GTx was co-founded by Mitchell S. Steiner and Marc S. Hanover in 1997. The company is based in Memphis, Tennessee.

SINOVAC BIOTECH LTD - ORDINARY SHARES (ANTIGUA/BARBUDO) (SVA)

Sinovac Biotech, Ltd. engages in the research, development, commercialization, and sale of human-use vaccines and related products for infectious diseases. It offers Healive, a vaccine for hepatitis A; Bilive, a combined vaccine for hepatitis A and B; and Anflu, a split flu vaccine. The company is also developing SARS vaccine, which is in phase I clinical trails, as well as has a co development agreement with the China Centre of Disease Control and Prevention for the development of Avian Flu-Pandemic Influenza Vaccine. Sinovac Biotech was founded in 1999 and is headquartered in Beijing, China.

NEUROGESX INC (NGSX)

NeurogesX, Inc., a biopharmaceutical company, engages in the development and commercialization of novel pain management therapies. It primarily focuses on chronic peripheral neuropathic pain, including postherpetic neuralgia (PHN), painful HIV-distal sensory polyneuropathy (HIV-DSP), and painful diabetic neuropathy (PDN). The company's lead product candidate NGX-4010 is a synthetic capsaicin-based topical patch to manage pain associated with peripheral neuropathic pain conditions, has completed two pivotal Phase 3 clinical trials in PHN and HIV-DSP. It is also developing NGX-1998, a non-patch liquid formulation of synthetic capsaicin, and an opioid analgesic for use in managing pain associated with other chronic pain conditions, such as cancer pain. The company was founded in 1998 as Advanced Analgesics, Inc. and changed its name to NeurogesX, Inc. in September 2000. NeurogesX is headquartered in San Carlos, California.

NANOSPHERE INC (NSPH)

Nanosphere, Inc. develops, manufactures, and markets a molecular diagnostics platform, the Verigene System, that enables genomic and protein testing on a single platform. Its proprietary nanoparticle technology provides the ability to run multiple tests at the same time on the same sample, and enables the development of various test assays to be performed on a single platform. The company is developing diagnostic tests for a range of medical conditions, including cancer, neurodegenerative, cardiovascular, and infectious diseases, as well as pharmaco-genomics or tests for personalized medicine. It is also developing other genomic assays, including tests for cystic fibrosis and a range of infectious diseases. In addition, the company has a program to develop protein tests based on established biomarkers and to validate new biomarkers, in which its ultra-sensitive protein detection technology enables earlier detection of various diseases. Nanosphere was founded in 1998 and is headquartered in Northbrook, Illinois.

ATHERSYS INC (ATHX)

Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes ATHX-105, a Phase I clinical trial product for the treatment of obesity. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders that include sleep disorders, such as narcolepsy or excessive daytime sleepiness; and other potential indications, such as attention deficit hyperactivity disorder and other cognitive disorders. In addition, Athersys, through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for bone marrow transplant/oncology support, ischemic stroke, and other disease indications. Athersys is based in Cleveland, Ohio.

AFFYMAX INC (AFFY)

Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions. Its lead product candidate includes Hematide, a synthetic peptide-based erythropoiesis stimulating agent, which is designed to treat anemia associated with chronic kidney disease and cancer. The company is conducting phase II clinical trials of Hematide in dialysis patients, predialysis patients, cancer patients on chemotherapy and patients with PRCA. It is also developing a pipeline of peptide based drug candidates, including Adeptide, a peptide based, non-injectable erythropoiesis stimulating agent; the Innotide program that comprises a family of peptide based drug candidates for use in the area of tissue protection in preclinical models of stroke, myocardial infarct, and renal injury; and Angiotide, a synthetic peptide for treating cancer by blocking angiogenesis, or blood vessel formation in tumors. Affymax has strategic alliances with Takeda Pharmaceutical Company Limited to develop and commercialize Hematide; EntreMed, Inc. for preclinical research of Angiotide; and Nektar Therapeutics AL, Corporation. The company was founded in 2001 and is based in Palo Alto, California.

ONCOTHYREON INC - COMMON SHARES (ONTY)

Oncothyreon, Inc., a biotechnology company, engages in the research and development of therapeutic products for the treatment of cancer primarily in the United States and Canada. It focuses on the development of synthetic vaccines for active specific immunotherapy. The company's lead cancer vaccine candidate is a synthetic MUC-1 peptide vaccine, Stimuvax, for the treatment of non-small cell lung cancer under Phase III clinical development. It is also developing MUC 1-based liposomal glycolipopeptide cancer vaccine, BGLP40 liposome, for use in various cancer indications. BGLP40 liposome vaccine is in pre-clinical development. In addition, the company, through its subsidiary, ProlX Pharmaceuticals Corporation, is developing small-molecule drugs that inhibit redox and cell-survival signalling proteins. This product line includes PX-12, a small molecule inhibitor of thioredoxin under Phase I trial; PX-478, a small molecule inhibitor of hypoxia inducible factor-1alpha, which is in late stage pre-clinical development; PX-866, an inhibitor of the phosphatidylinositol-3-kinase (PI-3-kinase)/PTEN/Akt pathway in late pre-clinical development; and PX-316, which is in preclinical development for the treatment of colon cancer and breast cancer. Oncothyreon has a product development, licensing, and co-promotion collaboration agreement with Merck KGaA. The company was founded in 1985. It was formerly known as Biomira, Inc. and changed its name to Oncothyreon, Inc. in December 2007. The company is based in Bellevue, Washington.

CELSION CORPORATION (CLSN)

Celsion Corporation, a biotechnology company, engages in the development and commercialization of products for the treatment of various types of cancer in the United States. It develops and commercializes oncology drugs, including tumor-targeting treatments using focused heat energy in combination with heat activated drug delivery. The company's ThermoDox, an encapsulation of doxorubicin, a common oncology drug, in a heat activated liposome, which is in Phase I clinical studies for the treatment of liver cancer and breast cancer. Celsion Corporation has research, license, or commercialization agreements with institutions, such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, Cleveland Clinic, and North Shore Long Island Jewish Health System. The company was founded in 1982 under the name Cheung Laboratories and later changed its name to Celsion Corporation. Celsion Corporation is based in Columbia, Maryland.

REPROS THERAPEUTICS INC (RPRX)

Repros Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development of drugs to treat hormonal and reproductive system disorders. The company's lead compound includes Proellex, a Phase II clinical trial product, for the treatment of uterine fibroids and endometriosis; and Androxal, a Phase III clinical trial product, which causes increased testosterone secretion from the testes, for the treatment of testosterone deficiency in men resulting from secondary hypogonadism. It also offers phentolamine-based products, such as VASOMAX for the treatment of male erectile dysfunction under the brand name, Z-Max, as well as Bimexes, an oral therapy for men with mild to moderate impotence, and ERxin, an injectable therapy for the treatment of severe erectile dysfunction. The company, formerly known as Zonagen, Inc., was founded in 1987 and changed its name to Repros Therapeutics, Inc. in 2006. Repros Therapeutics is based in The Woodlands, Texas.

OPEXA THERAPEUTICS INC (OPXA)

Opexa Therapeutics, Inc., a development stage biopharmaceutical company, develops autologous cellular therapies for the treatment of multiple sclerosis, rheumatoid arthritis, diabetes, and cardiovascular diseases. Its therapies are based on the company's T-cell and adult stem cell technologies. The company's lead product, Tovaxin is a T-cell-based therapeutic vaccine for multiple sclerosis, which is in Phase IIb clinical trials to treat the disease by inducing an immune response against the autoimmune myelin peptide-reactive T-cells. Opexa Therapeutics also holds a license for T-cell vaccination technology for rheumatoid arthritis, which allows the isolation of pathogenic T-cells from synovial fluid drawn from a patient, as well as holds a license to a stem technology, which enables production of adult multipotent stem cells from mononuclear cells of peripheral blood for use in autologous therapy. It engages in preclinical development of stem cell therapy for indications in diabetes mellitus. The company was founded in 2003. It was formerly known as PharmaFrontiers Corp. and changed its name to Opexa Therapeutics, Inc. in 2006. Opexa Therapeutics is based in the Woodlands, Texas.

MEDICINOVA INC (MNOV)

MediciNova, Inc., a biopharmaceutical company, engages in the acquisition and development of small molecule therapeutics worldwide. The company's clinical products under development include MN-001 for the treatment of bronchial asthma, which is in Phase III clinical program; MN-221 for the treatment of status asthmaticus, which is in Phase II clinical trial; MN-166 for the treatment of multiple sclerosis that is in a two year randomized, double-blind, placebo-controlled multi-center Phase II clinical trial; and MN-001 for the treatment of interstitial cystitis, which completed a Phase II/III clinical trial. It also develops MN-029 for the treatment of solid tumors, which completed Phase I clinical trial; MN-305 for the treatment of generalized anxiety disorder, which completed a Phase II/III clinical trial; MN-305 for the treatment of insomnia that is in Phase II clinical trial; and MN-221 for the treatment of preterm labor, which is in Phase Ib clinical study. In addition, the company develops MN-246 for the treatment of urinary incontinence, which completed a double-blind, randomized, placebo-controlled, single escalating dose Phase I clinical trial; MN-447 for the treatment of thrombotic disorders, which is in preclinical development stage; and MN-462 for the treatment of thrombotic disorders, which is in preclinical development stage. MediciNova, Inc. has strategic alliances with Kissei Pharmaceutical Co, Ltd.; Kyorin Pharmaceutical; Mitsubishi Pharma Corporation; Meiji Seika Kaisha, Ltd.; and Angiogene Pharmaceuticals, Ltd. The company was founded in 2000 and is headquartered in San Diego, California.

IDERA PHARMACEUTICALS INC (IDRA)

Idera Pharmaceuticals, Inc., a biotechnology company, engages in the discovery and development of synthetic DNA and RNA-based compounds for the treatment of cancer, infectious diseases, autoimmune diseases, asthma/allergies, and for use as vaccine adjuvants. It designs proprietary product candidates that are designed to modulate immune responses through Toll-like Receptors, the body's first line of immune defense. The company's DNA chemistry enables it to identify product candidates for the internal development programs and creates opportunities for multiple collaborative alliances. Its drug candidates include IMO-2055, an agonist of TLR9, which is in Phase II trial for renal cell carcinoma; and IMO-2125, a lead product candidate for treating infectious diseases. The company is collaborating with Merck & Co., Inc. to research, develop, and commercialize vaccine products containing its TLR7, 8, or 9 agonists in the fields of oncology, infectious diseases, and Alzheimer's disease. It is also collaborating with Novartis International Pharmaceutical, Ltd. to discover, develop, and commercialize TLR9 agonists for the treatment of asthma and allergies. Idera Pharmaceuticals was founded in 1989. The company was formerly known as Hybridon, Inc. and changed its name to Idera Pharmaceuticals, Inc. in 2005. Idera Pharmaceuticals is based in Cambridge, Massachusetts.

TENGION INC (TNGN)

Tengion, Inc., a regenerative medicine company, focuses on discovering, developing, manufacturing, and commercializing a range of replacement organs and tissues, or neo-organs and neo-tissues to address unmet medical needs in urologic, renal, gastrointestinal and vascular diseases. It creates these functional neo-organs and neo-tissues using a patientÂ's own cells, or autologous cells, in conjunction with the companyÂ's Organ Regeneration Platform. The companyÂ's lead product candidate, the Neo-Urinary Conduit, is an autologous implant that catalyzes regeneration of native-like bladder tissue for bladder cancer patients requiring a urinary diversion following bladder removal, or cystectomy. Its product pipeline also includes various candidates in early stage development, such as Neo-Kidney Augment for patients with advanced chronic kidney disease, or CKD. The company was founded in 2003 and is headquartered in East Norriton, Pennsylvania.

DYAX CORP (DYAX)

Dyax Corp. engages in the discovery, development, and commercialization of antibodies, small proteins, and peptides as therapeutic products, particularly in the areas of inflammation and oncology. As of December 31, 2004, the company had two product candidates in, or entering into, Phase II clinical trials for three indications. DX-88 is being studied for the treatment of both hereditary angioedema and for the prevention of blood loss, and other systemic inflammatory responses in on-pump open-heart surgery and other surgical indications, and DX-890 is being studied for the treatment of cystic fibrosis. In collaboration with Genzyme Corporation, Dyax is conducting an open-label, repeat dose Phase II clinical trial of DX-88. It has completed a Phase I/II study of DX-88 in the United States in patients undergoing coronary artery bypass grafting surgery. The company in collaboration with Debiopharm S.A. for DX-890 has completed two Phase IIa clinical trials, one in adults and one in pediatric cystic fibrosis patients. It uses its proprietary, patented technology, known as phage display, to identify a range of compounds consisting of monoclonal antibodies, small proteins, and peptides with the potential for the treatment of various diseases. The company has 12 discovery programs underway: 7 in oncology, which are focused on the discovery and development of therapies that fight cancer; 4 focused on targets that are believed to be mediators of inflammation; and 1 program focused on an infectious disease target. The company has collaboration agreements with AstraZeneca AB; Dendreon Corporation; Baxter Healthcare S.A.; Biogen Idec, Inc.; Inhibitex, Inc.; Debiopharm S.A.; and Syntonix Pharmaceuticals, Inc. Dyax was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.

ACADIA PHARMACEUTICALS INC (ACAD)

ACADIA Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for the treatment of central nervous system disorders. The company has four drug programs in clinical development and in preclinical and discovery stages. Its three clinical programs are ACP-103 for treatment-induced dysfunctions in Parkinson's disease, which is in phase II clinical trails; and ACP-103 and ACP-104, for the treatment of schizophrenia. In addition, the company has neuropathic pain program in Phase I clinical trials and a glaucoma program in preclinical development in collaboration with Allergan, Inc. ACADIA Pharmaceuticals was founded by Mark R. Brann. The company was incorporated as Receptor Technologies, Inc. in 1993 and is headquartered in San Diego, California.

CYCLACEL PHARMACEUTICALS INC (CYCC)

Cyclacel Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery, development, and commercialization of mechanism-targeted drugs to treat human cancers and various serious disorders. The company is evaluating seliciclib (CYC202), an orally available cyclin dependent kinase inhibitor, which is in Phase II clinical trials for the treatment of lung cancer. Its product candidates also comprise sapacitabine, an orally available nucleoside analog, which is in phase I clinical trial; and CYC116, an orally-active Aurora kinases inhibitor for the treatment of cancer. In addition, the company has preclinical stage programs for the treatment of cancer, inflammatory kidney disease, HIV/AIDS, and type 2 diabetes. Cyclacel Pharmaceuticals is headquartered in Berkeley Heights, New Jersey.

CYTOKINETICS INCORPORATED (CYTK)

Cytokinetics Incorporated, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel small molecule drugs that specifically target the cytoskeleton. Cytoskeleton is a diverse, multi-protein framework that carries out fundamental mechanical activities of cells including mitosis, or the division of genetic material during cell division, intracellular transport, cell movement and contraction, and overall cell organization. The company's focus on the cytoskeleton enables it to develop novel drugs for cancer, cardiovascular, fungal, and other diseases. It has two drug candidates, SB-715992 and SB-743921, which are in the phase-1 and phase-2 clinical trial, and a novel drug candidate for the treatment of congestive heart failure. Cytokinetics has strategic alliances with GlaxoSmithKline and AstraZeneca AB. The company was co-founded by Ronald D. Vale, Lawrence S. B. Goldstein, and James A. Spudich in 1997. Cytokinetics is headquartered in San Francisco, California.

BIONOVO INC (BNVI)

Bionovo, Inc. engages in the discovery and development of drugs in the areas of cancer and women's health primarily in the United States. It develops drugs to treat breast and ovarian cancers, and for menopause. The company's product and drug pipeline includes MF101, a selective estrogen receptor beta agonist, which is in Phase II trial to alleviate the symptoms of menopause, including hot flashes, night sweats, and bone mineral loss; and BZL101, an apoptosis inducing factor translocator/activator, which completed Phase I clinical trial, is an anticancer agent for breast, pancreatic, and ovarian cancers, and used for the treatment of other solid tumors. Its preclinical drug pipeline includes AA102, an apoptosis inducer, which would be used as an anticancer agent that attenuates mitochodrial membrane potential to cause a cytochrome c release and caspase activation to induce apoptosis; and VG101, an intra-vaginal gel for the treatment of postmenopausal vaginal dryness. The company has collaboration with the University of California at San Francisco; University of California at Berkeley; University of California at Davis; University of Texas, Southwestern; and University of Colorado Health Sciences College. Bionovo was founded in 2002 and is headquartered in Emeryville, California.

ALNYLAM PHARMACEUTICALS INC (ALNY)

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapeutic products based on RNA interference (RNAi) in the United States. The company is developing a pipeline of RNAi products using Direct RNAi to treat ocular, central nervous system, and respiratory diseases; and Systemic RNAi to treat a range of diseases, including oncology, metabolic, and autoimmune diseases. Its RNAi development programs are focused on an eye disease, known as age-related macular degeneration; and on a lung infection caused by a virus, known as human respiratory syncytial virus. The company also has multiple preclinical programs in Direct RNAi focused on a central nervous system disorder, known as Parkinson's disease; spinal cord injury; and a genetic disease, known as cystic fibrosis. In addition, Alnylam offers nontherapeutic license agreements to life science reagent and service providers. The company has strategic alliances and research collaborations with Merck &amp; Co., Inc.; Medtronic, Inc.; Cystic Fibrosis Foundation Therapeutics, Inc.; Mayo Foundation for Medical Education and Research; Novartis AG; and Mayo Clinic Jacksonville. Alnylam was founded by Phillip Sharp, Paul Schimmel, David Bartel, Thomas Tuschl, and Phillip Zamore in 2002. The company is headquartered in Cambridge, Massachusetts.

ARCA BIOPHARMA INC (ABIO)

ARCA biopharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of genetically-targeted therapies for heart failure and other cardiovascular diseases in the United States. The companyÂ's lead product candidate includes Gencaro, a pharmacologically beta-blocker and mild vasodilator for the treatment of chronic heart failure and other indications. It also focuses on the development of NU172, a short-acting anticoagulant used during medical or surgical procedures, which has completed Phase Ib clinical study. ARCA biopharma has a collaboration agreement with LabCorp to develop the Gencaro Test, a companion test for the genetic markers that predict clinical response to Gencaro. The company is headquartered in Broomfield, Colorado.

TRANSITION THERAPEUTICS INC - (CANADA) ORDINARY SHARES (TTHI)

Transition Therapeutics, Inc., a biopharmaceutical company, develops novel therapeutics for various disease indications. Its lead products include ELND-005/AZD-103 for the treatment of Alzheimer's disease, and regenerative therapies E1-I.N.T. and GLP1-I.N.T. for the treatment of diabetes. ELND-005/AZD-103 completed multiple Phase I clinical studies and E1-I.N.T. completed a Phase IIa clinical trial. GLP1-I.N.T. is under preparation for Phase II clinical development. The company is also developing MS-I.E.T. for the treatment of multiple sclerosis and HCV-I.E.T. for the treatment of hepatitis C. In addition, Transition Therapeutics has an emerging pipeline of preclinical drug candidates developed using its proprietary drug discovery engine. The company has a partnership with Elan Pharma International Limited for the development and commercialization of ELND-005/AZD-103 therapeutic agent. Transition Therapeutics was founded in 1987. It was formerly known as Transition Therapeutics and Diagnostics, Inc. and changed its name to Transition Therapeutics, Inc. in 2000. The company is based in Toronto, Canada.

ANTHERA PHARMACEUTICALS INC (ANTH)

Anthera Pharmaceuticals, Inc., a development stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat diseases associated with inflammation, including cardiovascular and autoimmune diseases. Its primary product candidates include varespladib methyl (A-002), which has completed its Phase 2 clinical studies for the treatment of acute coronary syndrome; varespladib sodium (A-001) that is in a Phase 2 clinical study for the prevention of acute chest syndrome associated with sickle cell disease; and A-623, which has completed Phase 1 clinical studies for the treatment of B-cell mediated autoimmune diseases. The company has license agreements with Eli Lilly and Company, and Shionogi & Co., Ltd. to develop and commercialize secretory phospholipase A2 or sPLA2 inhibitors for the treatment of cardiovascular disease and other diseases; and Amgen Inc., to develop and commercialize A-623. Anthera Pharmaceuticals, Inc. was founded in 2004 and is headquartered in Hayward, California.

DARA BIOSCIENCES INC (DARA)

DARA BioSciences, Inc., a development-stage pharmaceutical company, develops a portfolio of therapeutic candidates for neuropathic pain, dermatological disorders, and metabolic diseases, including type 2 diabetes. It is developing a Phase 2a clinical trial candidate, KRN5500, for the treatment of neuropathic pain. The company also has various preclinical therapeutic candidates, including DB160, DB959, DB900, and DB200 for the treatment of metabolic diseases, dermatology, chronic neuropathic pain, Parkinson's disease, cardiovascular, and central nervous system disorders. The company is based in Raleigh, North Carolina.

MARINA BIOTECH (MRNA)

MDRNA, Inc. operates as a biotechnology company developing RNA-based technologies, including therapeutics based on RNA interference (RNAi) and microRNA. The company's primary focus is on the delivery of siRNAs in the treatment of a range of human diseases, including inflammation, viral infections, cancer, and metabolic disorders. MDRNA is pursuing pre-clinical RNAi programs in influenza and rheumatoid arthritis, from which it would identify appropriate target candidates for partnering and clinical development. The company has been building patent estates in the RNAi field, with approximately 260 filed patents addressing 144 gene sequences, including disease-validated targets. It seeks to monetize its nasal drug delivery business through licensing, partnering, or acquisition of its Phase II intranasal programs. MDRNA, Inc. was formerly known as Nastech Pharmaceutical Company, Inc. and changed its name to MDRNA, Inc. in June 2008. The company was incorporated in 1983 and is headquartered in Bothell, Washington.

ANADYS PHARMACEUTICALS INC (ANDS)

Anadys Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing small molecule medicines for the treatment of hepatitis C virus (HCV), hepatitis B virus (HBV), and certain bacterial infections. The company's primary clinical development programs include ANA975, an oral prodrug of isatoribine for the treatment of HCV and HBV, and ANA380 for the treatment of HBV. ANA975, which is in phase I clinical trails, is a proprietary chemical entity that is administered orally and then is converted into the active compound, resulting in isatoribine in the bloodstream. ANA380 is in phase II clinical trails in patients with lamivudine-resistant, or lamR, hepatitis B virus. The company also has discovery programs exploring the use of oral prodrugs of TLR-7 agonists and direct antiviral discovery efforts focused on structural-based drug design. In addition, it develops a class of molecules that act against certain bacterial infections, including hospital-based infections, by inhibiting ribosomal function, which is the ability to synthesize new proteins. Anadys Pharmaceuticals has collaborative agreements with Amgen, Inc. and Daiichi Pharmaceutical Co. Ltd. to discover compounds against therapeutic targets of Amgen and Daiichi; and with Aphoenix, Inc. to discover and advance compounds against Aphoenix targets for multiple therapeutic indications. The company was incorporated in 1992 under the name ScripTech Pharmaceuticals, Inc. It changed its name to Scriptgen Pharmaceuticals, Inc. in 1994 and to Anadys Pharmaceuticals, Inc. in 2000. Anadys Pharmaceuticals is headquartered in San Diego, California.

PALATIN TECHNOLOGIES INC (PTN)

Palatin Technologies, Inc., a biopharmaceutical company, engages in the discovery and development of melanocortin (MC)-based therapeutics in the United States. It markets NeutroSpec, a proprietary radiolabeled monoclonal antibody product, for imaging and diagnosing equivocal appendicitis. The company also conducts additional clinical trials with NeutroSpec and evaluating its potential as an imaging agent for osteomyelitis, post-surgical infection, and inflammatory bowel disease. Its PT-141, a clinical development stage nasally-administered peptide, which would be used for the treatment of both male and female sexual dysfunction. In addition, the company has preclinical development programs based on the MC family, which would be used for various therapeutic indications, including obesity and cachexia; and a program for congestive heart failure. The company has a strategic collaboration agreement with Mallinckrodt Imaging for marketing and distributing NeutroSpec; and a collaborative development and marketing agreement with King Pharmaceuticals, Inc., to jointly develop and commercialize PT-141. Palatin Technologies was incorporated in 1986 and is based in Cranbury, New Jersey.

OXYGEN BIOTHERAPEUTICS INC (OXBT)

Oxygen Biotherapeutics, Inc. focuses on commercializing pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. The company has under development a perfluorocarbon (PFC) therapeutic oxygen carrier and liquid ventilation product (Oxycyte) and has out-licensed an implantable glucose sensor. Its products are based upon core technologies that include biomedical applications for PFCs, and medical and industrial applications for biosensors. Oxycyte has the potential for use in multiple indications, including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. The company was formerly known as Synthetic Blood International, Inc. and changed its name to Oxygen Biotherapeutics, Inc. in June 2008. Oxygen Biotherapeutics was founded in 1967 and is based in Durham, North Carolina.

XOMA LTD (XOMA)

XOMA, Ltd., a biopharmaceutical company, engages in the development and manufacture of antibodies and other genetically-engineered protein products to treat immunological and inflammatory disorders, cancer, and infectious diseases. The company's proprietary and collaborative product development programs include RAPTIVA, a humanized therapeutic monoclonal antibody, for the treatment of adults for moderate to severe plaque psoriasis; CHIR-12.12, an anti-CD40 antagonist antibody intended as a treatment for B-cell malignancies; and NEUPREX, a Phase II clinical trial product, IV formulation of rBPI21, a modified recombinant fragment of bactericidal/permeability-increasing protein for multiple anti-infective and antiendotoxin indications. Its development products also comprise MLN2222, a Phase II clinical trial product, a complement inhibitor under development to reduce the incidence of complications in patients undergoing surgical procedures involving the use of cardiopulmonary bypass; Gastrin, a preclinical antigastrin antibody, for Gastric cancers; ING-1, a Phase I clinical trial product, Human Engineered antibody to Ep-CAM for Adenocarcinomas; and XMP.629, a topical formulation of BPI derived antimicrobial peptide fro acne. XOMA, Ltd. also licenses its proprietary technologies relating to bacterial expression of recombinant pharmaceutical products, as well as its Human Engineering technology that allows modification of any nonhuman monoclonal antibody to reduce or eliminate detectable immunogenicity in humans to biotechnology and pharmaceutical companies. It has collaboration and license agreements with Genentech, Inc.; Chiron Corporation; Zephyr Sciences, Inc.; Millennium Pharmaceuticals, Inc.; Aphton Corporation; Merck &amp; Co., Inc.; Lexicon Genetics Incorporated; Cubist Pharmaceuticals, Inc.; and Triton BioSystems, Inc. The company was founded by Patrick J. Scannon. XOMA, Ltd. was incorporated in 1981 and is headquartered in Berkeley, California.

ICAGEN INC (ICGN)

Icagen, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of orally-administered small molecule drugs that modulate ion channel targets. The company's four advanced programs include ICA-17043, an inhibitor of the Gardos channel, for the chronic treatment of sickle cell disease, which is in Phase III clinical trials; a lead compounds for epilepsy and neuropathic pain, which is under preclinical studies; a compound for atrial fibrillation, which is being developed by its collaborator Bristol-Myers Squibb Company and is in phase I clinical trials; and a compound for dementia, including Alzheimer's disease, which is being developed by its collaborator Yamanouchi Pharmaceutical Co., Ltd. and is undergoing advanced preclinical testing. In addition, it conducts drug discovery programs focused on new therapeutics for pain disorders, inflammatory disorders, and glaucoma. Icagen has collaboration and copromotion agreements with McNeil Consumer &amp; Specialty Pharmaceuticals Division of McNeil-PPC, Inc. relating to the development and commercialization of ICA-17043; and with Abbott Laboratories to discover, develop, and market compounds that act on specified ion channel targets for the treatment of neuropathic pain and with application in urology, including the treatment of urinary incontinence. The company was co-founded by P. Kay Wagoner and H. Jefferson Leighton. It was incorporated in 1992 and is based in Durham, North Carolina.